

# World Journal of *Pharmacology*

*World J Pharmacol* 2013 June 9; 2(2): 47-64



## Editorial Board

2011-2015

The *World Journal of Pharmacology* Editorial Board consists of 477 members, representing a team of worldwide experts in pharmacology. They are from 44 countries, including Argentina (1), Australia (12), Austria (3), Belarus (1), Belgium (3), Brazil (5), Bulgaria (1), Canada (13), Chile (2), China (45), Czech Republic (2), Denmark (2), Egypt (2), Finland (3), France (13), Germany (7), Greece (17), Hungary (6), Iceland (1), India (10), Iran (4), Ireland (1), Israel (13), Italy (40), Japan (31), Malaysia (1), Mexico (1), Netherlands (11), New Zealand (2), Poland (3), Portugal (2), Russia (1), Saint Kitts and Nevis (1), Saudi Arabia (1), Serbia (1), Singapore (7), South Korea (10), Spain (22), Sweden (4), Switzerland (2), Thailand (2), Turkey (6), United Kingdom (21), and United States (141).

### EDITOR-IN-CHIEF

Geoffrey Burnstock, *London*

### GUEST EDITORIAL BOARD MEMBERS

Chia-Hsiang Chen, *Zhunan*  
 Jong-Yuh Cherng, *Chia-yi*  
 Jia-You Fang, *Taoyuan*  
 Ming-Fa Hsieh, *Chung Li*  
 Dong-Ming Huang, *Miaoli County*  
 Tsong-Long Hwang, *Taoyuan*  
 Jjiang-Huei Jeng, *Taipei*  
 Mei-Chuan Ko, *Taipei*  
 Po-Lin Kuo, *Kaohsiung*  
 Hsien-Yuan Lane, *Taichung*  
 Chen-Lung Steve Lin, *Kaohsiung*  
 Min-Hsiung Pan, *Kaohsiung*  
 Joen-Rong Sheu, *Taipei*  
 Chih-Hsin Tang, *Taichung*  
 Chin-Hsiao Tseng, *Taipei*  
 Chih-Shung Wong, *Taipei*  
 Sheng-Nan Wu, *Tainan*  
 Wen-Bin Wu, *Taipei*  
 Chuen-Mao Yang, *Taoyuan*

### MEMBERS OF THE EDITORIAL BOARD



**Argentina**

Alicia Beatriz Motta, *Buenos Aires*



**Australia**

Jonathon C Arnold, *Sydney*  
 Alexander Bobik, *Melbourne*

Stephen John Clarke, *Artarmon*  
 Brian Dean, *Melbourne*  
 Xiao-Jun Du, *Melbourne*  
 Cherrie A Galletly, *Adelaide*  
 Andrew John Lawrence, *Parkville Vic*  
 Johnson Mak, *Victoria*  
 Des Raymond Richardson, *Sydney*  
 Shaun L Sandow, *Sydney*  
 Karly Calliopi Sourris, *Victoria*  
 Fanfan Zhou, *Sydney*



**Austria**

Andreas Bernkop-Schnurch, *Innsbruck*  
 Martin Hohenegger, *Vienna*  
 Siegfried Kasper, *Vienna*



**Belarus**

Peter Gregor Rytik, *Minsk*



**Belgium**

Van Dam D Charlotte Josephine, *Wilrijk*  
 Mark Van de Castele, *Brussels*  
 Mathieu Vinken, *Brussels*



**Brazil**

Mohammad Abdollahi, *Minas Gerais*  
 Frederic Frezard, *Minas Gerais*  
 Maria de N Correia Soeiro, *Rio de Janeiro*  
 Waldiceu Aparecido Verri Jr, *Londrina*  
 Angelina Zanesco, *Sao Paulo*



**Bulgaria**

Stanislav Gueorguiev Yanev, *Sofia*



**Canada**

Sylvain G Bourgoin, *Quebec*  
 Subrata Chakrabarti, *Ontario*  
 Thomas K H Chang, *Vancouver*  
 Janos G Filep, *Montreal*  
 Pierre A Guertin, *Quebec*  
 Bernard Le Foll, *Toronto*  
 Suhayla Mukaddam-Daher, *Quebec*  
 Claude Rouillard, *Quebec*  
 Jean Sevigny, *Quebec*  
 Ashok K Srivastava, *Quebec*  
 Margarey Danielle Weiss, *Vancouver*  
 Jonathan P Wong, *Medicine Hat*  
 Xi Yang, *Manitoba*



**Chile**

Javier Palacios, *Antofagasta*  
 Armando Rojas, *Talca*



**China**

George G Chen, *Hong Kong*  
 Chi-Hin Cho, *Hong Kong*  
 Li-Wu Fu, *Guangzhou*  
 Qin He, *Chengdu*  
 Qing-Yu He, *Guangzhou*  
 Yu Huang, *Hong Kong*  
 Xi-Qun Jiang, *Nanjing*

Tai-Yi Jin, *Shanghai*  
 Yiu Wa Kwan, *Hong Kong*  
 Ke Lan, *Chengdu*  
 Pak-Heng George Leung, *Hong Kong*  
 Jian-Jun Li, *Beijing*  
 Peng Liang, *Shenyang*  
 Zhi-Xiu Lin, *Hong Kong*  
 Xiao-Dong Liu, *Nanjing*  
 Xin-Yong Liu, *Jinan*  
 Yong-Yong Shi, *Shanghai*  
 Jing-Fang Wang, *Shanghai*  
 Yong-Qing Wang, *Nanjing*  
 William Ka Kei Wu, *Hong Kong*  
 Ruian (Ray) Xu, *Xiamen*  
 Xiaoqiang Yao, *Hong Kong*  
 Wei-Hai Ying, *Shanghai*  
 Shu-Biao Zhang, *Dalian*  
 Yu Zhang, *Beijing*  
 Cheng-Gang Zou, *Kunming*



#### Czech Republic

Vladimir Krystof, *Olomouc*  
 Kamil Kuca, *Hradec Kralove*



#### Denmark

Morten Grunnet, *Copenhagen*  
 Yasser Ahmed Mahmmoud, *Aarhus*



#### Egypt

Nagwa M Nour El Din, *Alexandria*  
 Manar Mahfouz Salem, *Tanta*



#### Finland

Seppo Kahkonen, *Helsinki*  
 Hannu Ilmari Kankaanranta, *Seinajoki*  
 Helder Almeida Santos, *Helsinki*



#### France

Christian Bronner, *Strasbourg*  
 Rene Bruno, *Marseille*  
 Marie-Chantal Canivenc-Lavier, *Dijon*  
 Bertrand Cariou, *Nantes*  
 Emmanuelle Corruble, *Le Kremlin Bicêtre*  
 Boue-Grabot Eric, *Bordeaux*  
 Siest Gerard, *Nancy*  
 Laurent Karila, *Villejuif*  
 Frederic Lagarce, *Angers*  
 Tanguy Nicolas Maurice, *Montpellier*  
 Fernando Rodrigues-Lima, *Paris*  
 Jean-Marc Sabatier, *Marseille*  
 Steeve Herve Thany, *Angers*



#### Germany

Axel Becker, *Magdeburg*  
 Thomas Efferth, *Mainz*  
 Walter E Haefeli, *Heidelberg*  
 Florian Lang, *Tubingen*  
 Huige Li, *Mainz*

Frank Thevenod, *Witten*  
 Michael Wink, *Heidelberg*



#### Greece

Panagiotis G Anagnostis, *Thessaloniki*  
 Ekaterini Chatzaki, *Alexandroupolis*  
 Vassilis J Demopoulos, *Thessaloniki*  
 Moses Elisaf, *Ioannina*  
 Panagiotis Ferentinos, *Athens*  
 Dimitrios Galaris, *Ioannina*  
 George Kolios, *Alexandroupolis*  
 Tzortzis Nomikos, *Athens*  
 Constantinos M Paleos, *Aghia Paraskevi*  
 George Panagis, *Rethymno*  
 Andreas Papapetropoulos, *Patras*  
 Kosmas I Paraskevas, *Athens*  
 George P Patrinos, *Patras*  
 Evangelos Rizos, *Ioannina*  
 Despina Sanoudou, *Athens*  
 Kostas Syrigos, *Athens*  
 Ioannis S Vizirianakis, *Thessaloniki*



#### Hungary

Albert Császár, *Budapest*  
 Peter Hamar, *Budapest*  
 Peter Krajcsi, *Budapest*  
 Gabor Maksay, *Budapest*  
 Attila Janos Miseta, *Cserkut*  
 Joseph Molnar, *Szeged*



#### Iceland

Hekla Sigmundsdottir, *Reykjavik*



#### India

VN Balaji, *Bangalore*  
 Chiranjib Chakraborty, *Vellore*  
 Naibedya Chattopadhyay, *Lucknow*  
 SJS Flora, *Gwalior*  
 Srinivas Gopala, *Thiruvananthapuram*  
 Seetharamappa Jaldappagari, *Dharwad*  
 Basavaraj K Nanjwade, *Karnataka*  
 Kishore Madhukar Paknikar, *Pune*  
 Vikas Anand Saharan, *Sri Ganganagar*  
 Abdus Samad, *delhi*



#### Iran

Mohammad Abdollahi, *Tehran*  
 Ahmad Reza Dehpour, *Tehran*  
 Mehrdad Hamidi, *Zanjan*  
 Arash Mowla, *Bushehr*



#### Ireland

Marek Witold Radomski, *Dublin*



#### Israel

Galila Agam, *Beer-Sheva*

Robert Henry Belmaker, *Beersheva*  
 Shomron Ben-Horin, *Tel-Hashomer*  
 Arik Dahan, *Beer-Sheva*  
 Hagit Eldar-Finkelman, *Rehovot*  
 Eliezer Flescher, *Tel Aviv*  
 Moshe Gavish, *Haifa*  
 Jacob George, *Rehovot*  
 Israel Hanukoglu, *Ariel*  
 Joseph Kost, *Beer-Sheva*  
 Irena Manov, *Haifa*  
 Mordechai Muszkat, *Jerusalem*  
 Michal Schwartz, *Rehovot*



#### Italy

Giuseppe Barbaro, *Rome*  
 Francesca Borrelli, *Naples*  
 Franco Borsini, *Pomezia*  
 Silvio Caccia, *Milan*  
 Giuseppe Maurizio Campo, *Messina*  
 Raffaele Capasso, *Naples*  
 Mauro Antonio Maria Carai, *Cagliari*  
 Dario Cattaneo, *Milan*  
 Davide Cervia, *Viterbo*  
 Giuseppe Cirino, *Napoli*  
 Emilio Clementi, *Milano*  
 Massimo Collino, *Torino*  
 Vincenzo Cuomo, *Rome*  
 Francesca Fallarino, *Perugia*  
 Tullio Florio, *Genova*  
 Vittorio Gentile, *Napoli*  
 Guido Grassi, *Milan*  
 Mario Grassi, *Trieste*  
 Annalisa Guaragna, *Napoli*  
 Milena Gusella, *Trecenta*  
 Francesco Impagnatiello, *Milan*  
 Angelo A Izzo, *Naples*  
 Luca La Colla, *Parma*  
 Giovanni Landoni, *Milan*  
 Aurelio Leone, *Castelnuovo Magra*  
 Mauro Magnani, *Urbino*  
 Mario Marchi, *Genova*  
 Silvia Marinelli, *Rome*  
 Robert Nistico, *Rome*  
 Francesco Parmeggiani, *Ferrara*  
 Sabina Passamonti, *Trieste*  
 Emilio Perucca, *Pavia*  
 Carlo Riccardi, *Perugia*  
 Graziano Riccioni, *Manfredonia*  
 Sergio Rutella, *Rome*  
 Gianni Sava, *Trieste*  
 Pier Andrea Serra, *Sassari*  
 Luca Steardo, *Rome*  
 Claudiu T Supuran, *Florence*  
 Gianluca Tettamanti, *Varese*



#### Japan

Katsuya Dezaki, *Tochigi*  
 Jun Fang, *Kumamoto*  
 Takahisa Furuta, *Hamamatsu*  
 Mitsuko Furuya, *Yokohama*  
 Osamu Handa, *Kyoto*  
 Hideaki Hara, *Gifu*  
 Kenji Hashimoto, *Chiba*  
 Zhi-Qing Hu, *Tokyo*  
 Toru Kobayashi, *Niigata*  
 Hiroshi Kunugi, *Tokyo*  
 Makoto Makishima, *Tokyo*

Takayuki Masaki, *Oita*  
 Shin-ichiro Miura, *Fukuoka*,  
 Noboru-Motohashi, *Tokyo*  
 Yuji Naito, *Kyoto*  
 Toshio Nakaki, *Tokyo*  
 Satomi Onoue, *Shizuoka*  
 Honoo Satake, *Osaka*  
 Masaharu Seno, *Okayama*  
 Yasuyuki Shimada, *Yuri-Honjo*  
 Mitsushige Sugimoto, *Hamamatsu*  
 Masafumi Takahashi, *Tochigi*  
 Shinji Takai, *Takatsuki*  
 Yoh Takuwa, *Kanazawa*  
 Shingo Tsuji, *Osaka*  
 Hirokazu Tsukahara, *Okayama*  
 Motoko Unoki, *Fukuoka*  
 Shizuo Yamada, *Shizuoka*  
 Norio Yasui-Furukori, *Hirosaki*  
 Yukio Yoneda, *Kanazawa*  
 Kiyotsugu Yoshida, *Bunkyo-ku*



#### Malaysia

Johnson Stanslas, *Serdang*



#### Mexico

Esus Adolfo Garcia-Sainz, *Col. Nápoles*



#### Netherlands

Arjan Blokland, *Maastricht*  
 Eliyahu Dremencov, *Groningen*  
 Elisa Giovannetti, *Amsterdam*  
 Hidde J Haisma, *Groningen*  
 Godefridus J Peters, *Amsterdam*  
 Frank A Redegeld, *Utrecht*  
 Harald H H W Schmidt, *Maastricht*  
 Martina Schmidt, *Groningen*  
 Frederik M van der Veen, *Rotterdam*  
 Charles J Vecht, *The Hague*  
 Joris Cornelis Verster, *Utrecht*



#### New Zealand

Hesham Al-Sallami, *Dunedin*  
 Lin Yang, *Dunedin*



#### Poland

Thomas Michal Brzozowski, *Cracow*  
 Wladyslawa Anna Daniel, *Krakow*  
 Andrzej Pilc, *Krakow*



#### Portugal

Bruno Filipe C Cardoso Sarmiento, *Porto*  
 Cristina Maria Sena, *Coimbra*



#### Russia

Roman Gerbertovich Efremov, *Moscow*



#### Saint Kitts and Nevis

Ignacio Lizarraga, *Baseterre*



#### Saudi Arabia

Mohamed Haidara, *Abha*



#### Serbia

Milan Jokanovic, *Belgrade*



#### Singapore

Jinsong Bian, *Singapore*  
 Gavin S Dawe, *Singapore*  
 Chang Ming Li, *Singapore*  
 Haishu Lin, *Singapore*  
 Rajkumar Ramamoorthy, *Singapore*  
 Gautam Sethi, *Singapore*  
 WS Fred Wong, *Singapore*



#### South Korea

Ki Churl Chang, *Jinju*  
 Jooheun Ha, *Seoul*  
 Sang June Hahn, *Seoul*  
 Byeongmoon Jeong, *Seoul*  
 Myung Gull Lee, *Bucheon*  
 Won Suk Lee, *Yongsan*  
 Seung-Yeol Nah, *Seoul*  
 Kyoungsoo Park, *Daegu*  
 Young-Hyun Yoo, *Pusan*  
 Soh Yunjo, *Jeonju*



#### Spain

José Luis Arias-Mediano, *Granada*  
 Pedro Emilio Bermejo, *Madrid*  
 Fermín Sánchez de Medina, *Granada*  
 Guillermo Elizondo, *Mexico*  
 Leandro Fernández-Pérez, *Las Palmas*  
 Cristina Fillat, *Barcelona*  
 J Adolfo Garcia-Sainz, *Mexico*  
 Angel Luis Montejo Gonzalez, *Salamanca*  
 Tomas Herraiz, *Madrid*  
 Miguel JA Lainez, *Valencia*  
 Jose Martinez Lanao, *Salamanca*  
 Angel Lanas, *Zaragoza*  
 Vicente Martinez, *Barcelona*  
 Faustino Mollinedo, *Salamanca*  
 Virginia Motilva, *Sevilla*  
 Gorka Orive, *Vitoria-Gasteiz*  
 Ricardo Enrique Perez-Tomas, *Barcelona*  
 S Rodriguez-Couto, *Donostia-San Sebastian*  
 Maria Eugenia Saez, *Seville*  
 Juan Sastre, *Valencia*  
 Juan L Tamargo, *Madrid*  
 Salvador Ventura Zamora, *Barcelona*



#### Sweden

Aleksander A Mathe, *Stockholm*

Sharma Hari Shanker, *Uppsala*  
 Marie-Louise G Wadenberg, *Kalmar*  
 Cang-Bao Xu, *Lund*



#### Switzerland

Stefan J Borgwardt, *Basel*  
 Felicien Karege, *Geneva*



#### Thailand

Rumi Ghosh, *Rayong*  
 Kanokwan Jarukamjorn, *Khon Kaen*



#### Turkey

Cengiz Abdollahi Akkaya, *Bursa*  
 Sule Apikoglu-Rabus, *Istanbul*  
 Fatih Canan, *Bolu*  
 Saygin S Eker, *Bursa*  
 Nese Tuncel, *Eskisehir*  
 Mehmet Yaman, *Elazig*



#### United Kingdom

Charalambos Antoniadis, *Oxford*  
 Sabine Bahn, *Cambridge*  
 Christopher John Bushe, *New Malden*  
 David J Chambers, *London*  
 Michael J Curtis, *London*  
 Rossen M Donev, *Swansea*  
 Marco Falasca, *London*  
 David James Grieve, *Belfast*  
 Alan Jeffrey Hargreaves, *Nottingham*  
 Mahmoud M Iravani, *London*  
 Nigel Irwin, *Coleraine*  
 Lin-Hua Jiang, *Leeds*  
 Veena Kumari, *London*  
 Kim Lawson, *Sheffield*  
 Debbi MacMillan, *Glasgow*  
 Elek-Molnar, *Bristol*  
 Stuart Anthony Rushworth, *Norwich*  
 Sunita Suri, *Nottingham*  
 Jinsheng Xu, *Bristol*  
 Alexander Victor Zholos, *Belfast*




#### United States

Nihal Ahmad, *Madison*  
 James David Adams Jr, *Los Angeles*  
 Gustav Akk, *St. Louis*  
 Karim A Alkadhi, *Houston*  
 Charles Antzelevitch, *Utica*  
 Hugo Ruben Arias, *Glendale*  
 Dominick L Auci, *Escondido*  
 Ross J Baldessarini, *Belmont*  
 Oleg A Barski, *Louisville*  
 Bjorn Bauer, *Duluth*  
 Chengpeng Bi, *Kansas*  
 Marco Bortolato, *Los Angeles*  
 Josh Burk, *Williamsburg*  
 William K Chan, *Stockton*  
 James J Chen, *Jefferson*  
 Zhe-Sheng Chen, *New York*  
 Beek Yoke Chin, *Boston*  
 Ting-Chao Chou, *New York*

Olivier Civelli, *Irvine*  
Brian S Cummings, *Athens*  
John A Dani, *Houston*  
Igor Elman, *Belmont*  
Keith M Erikson, *Greensboro*  
Eric R Fedyk, *Cambridge*  
Pingfu Feng, *Cleveland*  
William Douglas Figg, *Bethesda*  
Mitchell Phillip Fink, *Los Angeles*  
Masayuki Fukata, *Miami*  
Bolin Geng, *Waltham*  
Arup K Ghose, *West Chester*  
Alasdair M Gilfillan, *Bethesda*  
Neeraj Gupta, *Cambridge*  
James P Hardwick, *Rootstown*  
David W Hein, *Louisville*  
Lawrence A Hill, *Salt Lake*  
Huixiao Hong, *Jefferson*  
Andrew G Horti, *Baltimore*  
Eric Huang, *San Diego*  
Peng Huang, *Houston*  
Ying Huang, *Syracuse*  
Sally A Huston, *Athens*  
Basalingappa L Hungund, *Orangeburg*  
Kenneth A Jacobson, *Bethesda*  
Sabzali Javadov, *San Juan*  
Douglas Lee Jennings, *Detroit*  
Robert Thomas Jensen, *New York*  
Guang-Liang Jiang, *Irvine*  
Zhi-Gen Jiang, *Portland*  
Harish C Joshi, *Atlanta*  
Thomas Harold Kelly, *Lexington*  
Raouf A Khalil, *Boston*  
Arifulla Khan, *Seattle*  
Mattheos Koffas, *Buffalo*  
Zbigniew K Krowicki, *New Orleans*  
Macus Tien Kuo, *Houston*  
Young Jik Kwon, *Irvine*  
Lorenzo Leggio, *Tehran*  
Jinhe Li, *Abbott Park*  
Liwu Li, *Blacksburg*

Ching-Shwun Lin, *San Francisco*  
Yong Lin, *Albuquerque*  
Dong min Liu, *Blacksburg*  
Jie Liu, *Kansas City*  
Ming-Cheh Liu, *Toledo*  
Xiu Liu, *Jackson*  
Edythe D London, *Los Angeles*  
Jian Lu, *Baltimore*  
Rudolf Lucas, *Augusta*  
Qing Ma, *Buffalo*  
Iddo Magen, *Los Angeles*  
Gerald A Maguire, *Orange*  
Kenneth Maiese, *Newark*  
Stuart Maudsley, *Baltimore*  
Christopher Robert McCurdy, *Mississippi*  
Michael Robert McDevitt, *New York*  
Pamela A McKinley, *Detroit*  
Beverley-G-Van Meerveld, *Oklahoma City*  
Kapil-Mehta, *Houston*  
Murielle Mimeault, *Nebraska*  
Ashim Kumar Mitra, *Kansas City*  
Agostino Molteni, *Kansas City*  
Nader H Moniri, *Atlanta*  
Valentina Echeverria Moran, *Bay Pines*  
Sandeep Mukherjee, *Omaha*  
Masanori Onda, *Bethesda*  
Murat OZ, *Baltimore*  
Pal Pacher, *Bethesda*  
Hui-Lin Pan, *Houston*  
Weihong Pan, *Baton Rouge*  
Giulio Maria Pasinetti, *New York*  
Kennerly Sexton Patrick, *Charleston*  
George Perry, *San Antonio*  
James Porter, *Grand Forks*  
Lucas Pozzo-Miller, *Birmingham*  
Mei Qiang, *San Antonio*  
Baskaran Rajasekaran, *Pittsburgh*  
Jeff Reagan, *Woodside*  
Victoria Risbrough, *San Diego*  
Michael A Rogawski, *Sacramento*  
Steven Alan Rosenzweig, *Charleston*

Uwe Rudolph, *Belmont*  
Arnold E Ruoho, *Madison*  
Wolfgang Sadee, *Columbus*  
Ahmad R Safa, *Indianapolis*  
Stephen H Safe, *Houston*  
Shakil Ahmed Saghir, *Midland*  
Sanjeev Shangary, *Ann Arbor*  
Mahesh Chandra Sharma, *Washington*  
Anantha Shekhar, *Indianapolis*  
Riyi Shi, *West Lafayette*  
Amruthesh C Shivachar, *Houston*  
Blair Karina Simone, *Bethesda*  
Brij Bhan Singh, *Grand Forks*  
Xue-Long Sun, *Cleveland*  
Manjunath N Swamy, *El Paso*  
Yvette France Tache, *Los Angeles*  
Kevin Scott Thorneloe, *King of Prussia*  
Robin L Thurmond, *San Diego*  
Guochuan Emil Tsai, *Torrance*  
Tove Tuntland, *San Diego*  
N D Vaziri, *Orange*  
Libor Velisek, *New York*  
Christoph F Adam Vogel, *Sacramento*  
Christian Waeber, *Charlestown*  
Yu-Jui Yvonne Wan, *Kansas City*  
Qin Wang, *Birmingham*  
R Clinton Webb, *Augusta*  
Thomas Wisniewski, *New York*  
Wing Tak Jack Wong, *Stanford*  
Jie Wu, *Phoenix*  
Zheng-Xiong Xi, *Baltimore*  
Da-Liao Xiao, *Loma Linda*  
Lixia Yao, *King of Prussia*  
Hao Yin, *Cambridge*  
Xiaozhong Yu, *Seattle*  
Chang-Guo Zhan, *Lexington*  
Hanting Zhang, *Morgantown*  
Qunwei Zhang, *Louisville*  
Shuxing Zhang, *Houston*  
Bao-Ting Zhu, *Kansas City*  
Chang Zhi Zhu, *Abbott Park*



**REVIEW**

47 Ocular drug delivery systems: An overview

*Patel A, Cholkar K, Agrahari V, Mitra AK*

**APPENDIX** I-V Instructions to authors

**ABOUT COVER** *World Journal of Pharmacology* Editorial Board, William K Chan, PhD, Professor, Department of Pharmaceutics and Medicinal Chemistry, Thomas J. Long School of Pharmacy and Health Sciences, University of the Pacific, Stockton, CA 95211, United States

**AIM AND SCOPE** *World Journal of Pharmacology (World J Pharmacol, WJP, online ISSN 2220-3192, DOI: 10.5497)* is a peer-reviewed open access academic journal that aims to guide clinical practice and improve diagnostic and therapeutic skills of clinicians.

*WJP* covers topics concerning neuropsychiatric pharmacology, cerebrovascular pharmacology, geriatric pharmacology, anti-inflammatory and immunological pharmacology, antitumor pharmacology, anti-infective pharmacology, metabolic pharmacology, gastrointestinal and hepatic pharmacology, respiratory pharmacology, blood pharmacology, urinary and reproductive pharmacology, pharmacokinetics and pharmacodynamics, clinical pharmacology, and drug toxicology.

We encourage authors to submit their manuscripts to *WJP*. We will give priority to manuscripts that are supported by major national and international foundations and those that are of great basic and clinical significance.

**INDEXING/ABSTRACTING** *World Journal of Pharmacology* is now indexed in Digital Object Identifier.

**FLYLEAF** I-IV Editorial Board

**EDITORS FOR THIS ISSUE** Responsible Assistant Editor: *Shuai Ma* Responsible Science Editor: *Su-Xin Gou*  
 Responsible Electronic Editor: *Ya-Jing Lu*  
 Proofing Editor-in-Chief: *Lian-Sheng Ma*

**NAME OF JOURNAL**  
*World Journal of Pharmacology*

**ISSN**  
 ISSN 2220-3192 (online)

**LAUNCH DATE**  
 February 9, 2012

**FREQUENCY**  
 Quarterly

**EDITOR-IN-CHIEF**  
**Geoffrey Burnstock, PhD, DSc, FAA, FRCS (Hon), FRCP (Hon), FmedSci, FRS, Professor,** Autonomic Neuroscience Centre, University College Medical School, Royal Free Campus, Rowland Hill Street, London NW3 2PF, United Kingdom

**EDITORIAL OFFICE**  
 Jin-Lei Wang, Director  
 Xiu-Xia Song, Vice Director

*World Journal of Pharmacology*  
 Room 903, Building D, Ocean International Center,  
 No. 62 Dongsihuan Zhonglu, Chaoyang District,  
 Beijing 100025, China  
 Telephone: +86-10-85381891  
 Fax: +86-10-85381893  
 E-mail: [wjpharmaco@wjgnet.com](mailto:wjpharmaco@wjgnet.com)  
<http://www.wjgnet.com>

**PUBLISHER**  
 Baishideng Publishing Group Co., Limited  
 Flat C, 23/F, Lucky Plaza,  
 315-321 Lockhart Road, Wan Chai,  
 Hong Kong, China  
 Fax: +852-6555-7188  
 Telephone: +852-3177-9906  
 E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
<http://www.wjgnet.com>

**PUBLICATION DATE**  
 June 9, 2013

**COPYRIGHT**  
 © 2013 Baishideng. Articles published by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

**SPECIAL STATEMENT**  
 All articles published in this journal represent the viewpoints of the authors except where indicated otherwise.

**INSTRUCTIONS TO AUTHORS**  
 Full instructions are available online at [http://www.wjgnet.com/2220-3192/g\\_info\\_20100722180909.htm](http://www.wjgnet.com/2220-3192/g_info_20100722180909.htm)

**ONLINE SUBMISSION**  
<http://www.wjgnet.com/esp/>

## Ocular drug delivery systems: An overview

Ashaben Patel, Kishore Cholkar, Vibhuti Agrahari, Ashim K Mitra

Ashaben Patel, Kishore Cholkar, Vibhuti Agrahari, Ashim K Mitra, Division of Pharmaceutical Sciences, School of Pharmacy, University of Missouri-Kansas City, Kansas City, Missouri-64108, United States

Author contributions: Patel A and Cholkar K contributed equally to this paper; all the authors wrote the manuscript.

Correspondence to: Ashim K Mitra, PhD, Professor, Chairman, Division of Pharmaceutical Sciences, School of Pharmacy, University of Missouri-Kansas City, 2464 Charlotte Street, Kansas City, Missouri-64108, United States. [mitraa@umkc.edu](mailto:mitraa@umkc.edu)

Telephone: +1-816-2351615 Fax: +1-816-2355779

Received: December 25, 2012 Revised: March 21, 2013

Accepted: April 3, 2013

Published online: June 9, 2013

### Abstract

The major challenge faced by today's pharmacologist and formulation scientist is ocular drug delivery. Topical eye drop is the most convenient and patient compliant route of drug administration, especially for the treatment of anterior segment diseases. Delivery of drugs to the targeted ocular tissues is restricted by various precorneal, dynamic and static ocular barriers. Also, therapeutic drug levels are not maintained for longer duration in target tissues. In the past two decades, ocular drug delivery research acceleratedly advanced towards developing a novel, safe and patient compliant formulation and drug delivery devices/techniques, which may surpass these barriers and maintain drug levels in tissues. Anterior segment drug delivery advances are witnessed by modulation of conventional topical solutions with permeation and viscosity enhancers. Also, it includes development of conventional topical formulations such as suspensions, emulsions and ointments. Various nanoformulations have also been introduced for anterior segment ocular drug delivery. On the other hand, for posterior ocular delivery, research has been immensely focused towards development of drug releasing devices and nanoformulations for treating chronic vitreo-retinal diseases. These novel devices and/or formulations may help to surpass ocular barriers and associated side effects with conventional topical

drops. Also, these novel devices and/or formulations are easy to formulate, no/negligibly irritating, possess high precorneal residence time, sustain the drug release, and enhance ocular bioavailability of therapeutics. An update of current research advancement in ocular drug delivery necessitates and helps drug delivery scientists to modulate their think process and develop novel and safe drug delivery strategies. Current review intends to summarize the existing conventional formulations for ocular delivery and their advancements followed by current nanotechnology based formulation developments. Also, recent developments with other ocular drug delivery strategies employing *in situ* gels, implants, contact lens and microneedles have been discussed.

© 2013 Baishideng. All rights reserved.

**Key words:** Anatomy and physiology; Cornea; Contact lens; Drug delivery; Eye; Emulsions; Formulations; Implants; Liposomes; Nanomicelles; Ointments; Retina; Suspensions

**Core tip:** Drug delivery to targeted ocular tissues has been a major challenge to ocular scientist, for decades. Current review intends to summarize the existing conventional formulations for ocular delivery and their advancements followed by current nanotechnology based formulation developments. Also, recent developments with other ocular drug delivery strategies employing *in situ* gels, implants, contact lens and microneedles have been discussed.

Patel A, Cholkar K, Agrahari V, Mitra AK. Ocular drug delivery systems: An overview. *World J Pharmacol* 2013; 2(2): 47-64 Available from: URL: <http://www.wjgnet.com/2220-3192/full/v2/i2/47.htm> DOI: <http://dx.doi.org/10.5497/wjp.v2.i2.47>

### INTRODUCTION

The eye is a complex organ with a unique anatomy and physiology. The structure of eye can be divided into




Figure 1 Structure of the eye.

two main parts: anterior segment and posterior segment (Figure 1). Anterior segment of the eye occupies approximately one-third while the remaining portion is occupied by the posterior segment. Tissues such as cornea, conjunctiva, aqueous humor, iris, ciliary body and lens make up the anterior portion. Back of the eye or posterior segment of the eye include sclera, choroid, retinal pigment epithelium, neural retina, optic nerve and vitreous humor. The anterior and posterior segment of eye is affected by various vision threatening diseases. Diseases affecting anterior segment include, but not limited to glaucoma, allergic conjunctivitis, anterior uveitis and cataract. While, age-related macular degeneration (AMD) and diabetic retinopathy are the most prevalent diseases affecting posterior segment of the eye.

Topical instillation is the most widely preferred non-invasive route of drug administration to treat diseases affecting the anterior segment. Conventional dosage forms such as eye drops account for 90% of the marketed ophthalmic formulations. The reason may be attributed to ease of administration and patient compliance<sup>[1,2]</sup>. Nonetheless, the ocular bioavailability is very low with topical drop administration. Numerous anatomical and physiological constraints such as tear turnover, nasolachrymal drainage, reflex blinking, and ocular static and dynamic barriers pose a challenge and impede deeper ocular drug permeation<sup>[3]</sup>. Hence, less than 5% of topically applied dose reaches to deeper ocular tissues<sup>[4]</sup>. Also, it is difficult to achieve therapeutic drug concentration into posterior segment ocular tissues following topical eye drops instillation because of the above mentioned barriers. The drug can be delivered to the posterior segment ocular tissues by different mode of administrations such as intravitreal injections, periocular injections, and systemic administration. However, small volume of eye compared to whole body and presence of blood retinal barriers; makes systemic administration an impractical approach. Intravitreal injection is the most common and widely recommended route of drug administration to treat posterior ocular diseases. Though, the need of repeated eye puncture with intravitreal injections causes several side effects such as

endophthalmitis, hemorrhage, retinal detachment and poor patient tolerance<sup>[5]</sup>. The transscleral drug delivery with periocular administration route is evolved as an alternative mode of drug delivery to the posterior ocular tissues. Although transscleral delivery is comparatively easy, less invasive and patient compliant, drug permeation is compromised by ocular static and dynamic barriers. Ocular barriers to transscleral drug delivery include: static barriers *i.e.*, sclera, choroid and retinal pigment epithelium (RPE), and dynamic barriers, *i.e.*, lymphatic flow in the conjunctiva and episclera, and the blood flow in conjunctiva and choroid<sup>[6,7]</sup>.

To overcome the ocular drug delivery barriers and improve ocular bioavailability, various conventional and novel drug delivery systems have been developed such as emulsion, ointments, suspensions, aqueous gels, nanomicelles, nanoparticles, liposomes, dendrimers, implants, contact lenses, nanosuspensions, microneedles, and *in situ* thermosensitive gels for the earlier mention ocular diseases. This review will provide an overview on various conventional and novel ophthalmic drug delivery systems developed to deliver drug to diseased ocular tissues for the treatment of ocular diseases.

## CONVENTIONAL OCULAR DRUG DELIVERY SYSTEMS

Topical drop instillation into the lower precorneal pocket is a patient compliant and widely recommended route of drug administration. However, most of the topically administered dose is lost due to reflux blinking and only 20% (-7  $\mu\text{L}$ ) of instilled dose is retained in the precorneal pocket<sup>[8]</sup>. Concentration of drug available in the precorneal area acts as a driving force for its passive diffusion across cornea. However, for efficient ocular drug delivery with eye drops, high corneal permeation with longer drug cornea contact time is required. Several efforts have been made toward improving precorneal residence time and corneal penetration. To improve corneal permeation iontophoresis, prodrugs, ion-pair forming agents and cyclodextrins are employed<sup>[9-13]</sup>. There is a wide range of ophthalmic products available in the market out of which around 70% of prescriptions include conventional eye drops. The reasons may be due to ease of bulk scale manufacturing, high patient acceptability, drug product efficacy, stability and cost effectiveness.

### Topical liquid/solution eye drops

Topical drops are the most convenient, safe, immediately active, patient compliant and non-invasive mode of ocular drug administration. An eye drop solution provides a pulse drug permeation post topical drop instillation, after which its concentration rapidly declines. The kinetics of drug concentration decline may follow an approximate first order. Therefore, to improve drug contact time, permeation and ocular bioavailability; various additives may be added to topical eye drops such as viscosity enhancers,

permeation enhancers and cyclodextrins. Viscosity enhancers improve precorneal residence time and bioavailability upon topical drop administration by enhancing formulation viscosity. Examples of viscosity enhancers include hydroxy methyl cellulose, hydroxy ethyl cellulose, sodium carboxy methyl cellulose, hydroxypropyl methyl cellulose and polyalcohol<sup>[14-16]</sup>.

Permeation enhancers improve corneal uptake by modifying the corneal integrity. Other additives such as chelating agents, preservatives, surface active agents and bile salts were studied as possible permeation enhancers. Benzalkonium chloride, polyoxyethylene glycol ethers (lauryl, stearyl and oleyl), ethylenediaminetetra acetic acid sodium salt, sodium taurocholate, saponins and cremophor EL are the examples of permeation enhancers investigated for improving ocular delivery<sup>[17-19]</sup>. Addition of permeation enhancers to ocular solutions improves ocular drug bioavailability but few studies revealed a local toxicity with permeation enhancers<sup>[20]</sup>. Hence, research is still being conducted to modify the effect of permeation enhancers and evaluate their safety on corneal tissues. Hornof *et al.*<sup>[21]</sup> evidenced that polycarbophil-cysteine as an excipient did not damage the corneal tissue integrity and suggested that it could be safe for ocular formulations. Cyclodextrins act as carriers for hydrophobic drug molecules in aqueous solution. This helps to deliver drugs to the surface of biological membrane. Highly lipophilic biological membrane has much lower affinity towards hydrophilic cyclodextrins. Therefore, cyclodextrins remain in aqueous solution and the hydrophobic drug is absorbed by the biological membrane. Optimal bioavailability was achieved for eye drops with cyclodextrins concentration of < 15%<sup>[22]</sup>. Other applications of cyclodextrins in eye drop formulation were recently reviewed and described in detail elsewhere by Cholkar *et al.*<sup>[23]</sup>.

Among these approaches, viscosity enhancers and cyclodextrins suffer from the disadvantage of precorneal loss. In the case of penetration enhancers, care should be taken in the selection due to high sensitivity of ocular tissues. Hence, it leads to development of other conventional formulations approaches with inert carrier systems for ocular delivery of therapeutics. Conventional ocular formulations such as emulsions, suspensions, and ointments are developed to improve solubility, precorneal residence time and ocular bioavailability of drugs. In the current era of nanotechnology, these conventional formulations still retain their place, importance and capture the market at large. However, these formulations are associated with various side effects such as ocular irritation, redness, inflammation, vision interference and stability issues<sup>[24]</sup>. Currently, research is being conducted to improve *in vivo* performance of these carrier systems and to minimize their side effects<sup>[25]</sup>. Several attempts are also being made to deliver drugs to posterior ocular tissues with conventional formulations. In the following sections, attempts have been made to describe the recent efforts made to improve *in vivo* performance of conventional ocular formulation and reduce their side effects.


## Emulsions

An emulsion based formulation approach offers an advantage to improve both solubility and bioavailability of drugs. There are two types of emulsions which are commercially exploited as vehicles for active pharmaceuticals: oil in water (o/w) and water in oil (w/o) emulsion systems<sup>[26]</sup>. For ophthalmic drug delivery, o/w emulsion is common and widely preferred over w/o system. The reasons include less irritation and better ocular tolerance of o/w emulsion. Restasis<sup>TM</sup>, Refresh Endura<sup>®</sup> (a non-medicated emulsion for eye lubrication) and AzaSite<sup>®</sup> are the examples of currently marketed ocular emulsions in the United States. Several studies have demonstrated applicability of emulsions in improving precorneal residence time, drug corneal permeation, providing sustain drug release and thereby enhancing ocular bioavailability<sup>[27]</sup>.

In a recent study, Tajika *et al.*<sup>[28]</sup> demonstrated improved anti-inflammatory activity of prednisolone derivative, 0.05% [<sup>3</sup>H] difluprednate, with emulsion as vehicle. Results confirmed that in the rabbit eye, emulsion could deliver drug to the anterior ocular tissues with small amount of drug reaching posterior tissues following single and multiple topical drop instillation. Single and multiple topical drop instillation studies revealed highest radioactivity in cornea followed by iris-ciliary body > retina-choroid > conjunctiva > sclera > aqueous humor > lens > and vitreous humor. Post single drop administration,  $T_{max}$  for cornea, conjunctiva, lens, iris-ciliary body, aqueous and vitreous humor was 0.5 h while for retina-choroid was 1 h. Negligible amount of drug was quantified in systemic circulation. With repeated dose instillation,  $T_{max}$  for lens and retina-choroid was 8 and 0.5 h, respectively. After 168 h, a total dose of approximately 99.5% of radioactivity was excreted in urine and feces. This study suggests difluprednate emulsion as a potential candidate for treating anterior ocular inflammations.

Emulsions with lipid additives such as soyabean lecithin, stearylamine were evaluated as carrier systems for azithromycin to demonstrate better ocular performance and bioavailability<sup>[29]</sup>. A comparative study for azithromycin solution *vs* emulsion at different doses (3, 5 and 10 mg/mL azithromycin) was studied for tear elimination characteristics. *In vivo* studies were conducted in rabbits with topical drop administration. Emulsion, not only observed to behave as a vehicle for azithromycin but also slowed drug release, improved its chemical stability and precorneal residence time. Additionally, emulsion formulation improved the chemical stability ( $t_{1/2}$ ) of azithromycin at pH 5.0 and 7.0 relative to aqueous solutions. Altogether, results suggest that lipid emulsion could be a promising vehicle for ocular drug delivery.

Similarly, another novel approach is to derivatize active pharmaceutical ingredients (API), and improve its ocular bioavailability with an emulsion as carrier system. This strategy may help to reduce ocular irritancy and improve the effect of API. To test this hypothesis, Shen *et al.*<sup>[25]</sup> made attempts to improve emulsion biocompatibility for the flurbiprofen. In this study, a derivative of flurbi-



**Figure 2** Concentration-time profiles of flurbiprofen (in the aqueous humor after instillation of flurbiprofen axetil emulsion F2-F4, FB-Na eye drops and flurbiprofen axetil-oil solution in rabbits. F1 = 0.1 wt% of castor oil, 0.08 wt% of tween-80; F2 = 0.5 wt% of castor oil, 0.4 wt% of tween-80; F3 = 1.0 wt% of castor oil, 0.8 wt% of tween-80; and F4 = 2.5 wt% of castor oil, 4.0 wt% of tween-80 with 2.2 wt% and 0.1 wt% of glycerol and flurbiprofen respectively. Reproduced with permission from reference Shen *et al*<sup>[25]</sup>. FB: Flurbiprofen; FBA-EM: Flurbiprofen axetil emulsion.

profen, flurbiprofen axetil, with castor oil and tween-80 was used to prepare emulsion<sup>[30]</sup>. Four different emulsions with varying ratios of castor oil (0.1 wt%-2.5 wt%) and tween 80 (0.08 wt%-4 wt%) were prepared and labeled as F1, F2, F3 and F4 respectively. *In vivo* studies were conducted in male New Zealand albino rabbits with a topical drop instillation. Aqueous humor pharmacokinetic studies showed F2 emulsion (castor oil to tween 80 wt% ratio of 0.5:0.4) to be better relative to other emulsion formulations and solution. The F2 emulsion translocated high drug concentrations into aqueous humor, post topical drop administration, relative to 0.03% flurbiprofen sodium eye drops (Figure 2). Similarly, ocular irritation studies with F2 emulsion demonstrated better biocompatibility relative to other emulsions (F1, F3 and F4).

Several researchers have introduced mucoadhesive polymers such as chitosan and hydroxypropyl methyl cellulose ether for emulsion coating. Studies concluded that chitosan surface coating improves precorneal residence time of API and thereby ocular bioavailability. Indomethacin loaded o/w emulsion was prepared employing castor oil and polysorbate-80 and the resultant emulsion was surface coated by chitosan<sup>[31]</sup>. A comparative *in vivo* study for chitosan coated *vs* non-coated indomethacin emulsions were conducted in male albino rabbits with topical drop instillation. Tear fluid pharmacokinetic study showed that emulsion surface coating with chitosan improves emulsion mean residence time and also half-life by 1.5 and 1.8 times, respectively relative to non-coated emulsion. Indomethacin concentrations were quantified in cornea, conjunctiva and aqueous humor, post 1 h of emulsion instillation. Indomethacin concentrations with emulsion system were found to be about 5.3 and 8.2 times higher in cornea relative to conjunctiva and aque-

ous humor.

### Suspensions

Suspensions are another class of non-invasive ocular topical drop drug carrier systems. Suspension may be defined as dispersion of finely divided insoluble API in an aqueous solvent consisting of a suitable suspending and dispersing agent. In other words, the carrier solvent system is a saturated solution of API. Suspension particles retain in precorneal pocket and thereby improve drug contact time and duration of action relative to drug solution. Duration of drug action for suspension is particle size dependent. Smaller size particle replenishes the drug absorbed into ocular tissues from precorneal pocket. While on the other hand, larger particle size helps retain particles for longer time and slow drug dissolution<sup>[32]</sup>. Thus, an optimal particle size is expected to result in optimum drug activity. Several suspension formulations are marketed worldwide to treat ocular bacterial infections. TobraDex<sup>®</sup> suspension is one of the widely recommended commercial products for subjects responding to steroid therapy. TobraDex<sup>®</sup> is a combination product of antibiotic, tobramycin (0.3%), and steroid, dexamethasone (0.1%). The major drawback of this commercial product is high viscosity. Recently, Scoper *et al*<sup>[33]</sup> made attempts to reduce the viscosity of TobraDex<sup>®</sup> and to improve its *in vivo* pharmacokinetics along with bactericidal activity. The rationale behind developing this formulation was to improve the suspension formulation characteristics such as quality, tear film kinetics and tissue permeation. The new suspension (TobraDex ST<sup>®</sup>) consists of tobramycin (0.3%), and steroid, dexamethasone (0.05%). Suspension settling studies showed that new formulation had very low settling over 24 h (3%) relative to marketed TobraDex<sup>®</sup> (66%). Ocular distribution studies showed higher tissues concentrations of dexamethasone and tobramycin in rabbits treated with TobraDex ST<sup>®</sup> relative to TobraDex<sup>®</sup>. New suspension formulation was found to be more effective than TobraDex<sup>®</sup> against *Staphylococcus aureus* and *Pseudomonas aeruginosa*. Clinical studies in human subjects showed high dexamethasone concentrations in aqueous humor than TobraDex<sup>®</sup>. These results suggest that new suspension formulation to be an alternative to marketed suspension. This is because the new suspension possesses better formulation characteristics, pharmacokinetics, bactericidal characteristic and patient compliance than marketed TobraDex<sup>®</sup> suspension.

In another study, to treat dry eye, 4 wk, randomized, double masked, multicenter phase II clinical trials were conducted with rebamipide (OPC-12759) suspension<sup>[34]</sup>. Suspension formulation at two different doses, *i.e.*, 1% and 2% rebamipide were employed for this study, where placebo served as control. The efficacy and safety of suspension formulation were determined in human subjects following topical instillation. A dose dependent response was observed for placebo, 1% and 2% rebamipide suspension for both fluorescein corneal staining and Lis-

samine green conjunctival staining studies at 2 and 4 wk. Tear production showed no significant difference from baseline from day 1 to week 4. But, the tear film break up time showed significant change in 1% and 2% rebamipide relative to placebo. All the subjects receiving treatment with suspension rebamipide formulation reported improvement of 64.1% and 54.9% respectively than subjects receiving placebo. Dysgeusia, ocular irritation and nasopharyngitis adverse events were frequently observed in 27.2%, 29.1% and 30.4% patients receiving placebo, 1% and 2% suspension, respectively. Drug induced adverse effects such as eye irritation was observed in 3.9%, 2.9% and 2.0% subjects receiving placebo, 1% rebamipide and 2% rebamipide respectively. All these adverse effects were found to recover without any additional treatment. This 4 wk studies revealed that suspension formulations were well tolerated and both formulations were effective in treating dry eye. In some measures, of the two formulations, 2% rebamipide suspension was found to be more effective relative to 1% suspension.

### Ointments

Ophthalmic ointments are another class of carrier systems developed for topical application. Ocular ointment comprises of mixture of semisolid and a solid hydrocarbon (paraffin) that has a melting point at physiological ocular temperature (34 °C). The choice of hydrocarbon is dependent on biocompatibility. Ointments help to improve ocular bioavailability and sustain the drug release<sup>[35]</sup>.

Vancomycin HCl (VCM) is a glycopeptides antibiotic with an excellent activity against aerobic and anaerobic gram positive bacteria and methicillin and cephem resistant *Staphylococcus aureus* (MRSA). In spite of better activity of VCM, no appropriate topical formulation was available in the market. Better ocular tissue permeability of VCM was not expected in a normal eye but few clinical effects of VCM solution were reported in ocular disease treatment. The reason for the observed effects was hypothesized due to broken ocular barrier system, which might have improved drug permeation. Fukuda *et al*<sup>[36]</sup> studied the intraocular dynamics of vancomycin hydrochloride ophthalmic ointments in rabbits. Thus, authors made attempts to demonstrate ocular dynamics of VCM ophthalmic ointment (TN-011) with indications limited to extraocular MRSA infections. The minimum growth inhibitory concentration to treat MRSA bacterial infections was found to be 1.56 µg/g. *In vivo* studies were conducted in rabbits [normal *vs* *Bacillus subtilis* (BS) group]. The BS group was developed in cornea by injecting BS solution into the central portion of parenchyma. Treatment was by topical ocular ointment (1% VCM) administration to normal and BS group rabbit eye. In normal group, after 15 min, VCM concentration in cornea of 12.04 ± 4.73 µg/g was attained at 30 min which was decreased to 0.49 ± 0.97 µg/g at 120 min. On the other hand, VCM concentrations in BS group cornea was 25.60 ± 11.01 µg/g after 15 min and 3.68 ± 1.38 µg/g after 240 min of administration. The concentrations of VCM

were maintained above MIC levels, in MRSA infection induced BS group, a considerable benefit to the patients from TN-011 is expected.

In another study by Eguchi *et al*<sup>[37]</sup>, four different ointment formulation of vancomycin with varying concentrations (0.03%, 0.10%, 0.30% and 1.00%) were prepared in 1:4 mixtures of liquid paraffin and vaseline. The efficacy of formulations was evaluated in rabbit model of MRSA keratitis infection after topical application. It was observed that at low drug concentrations, *i.e.*, 0.03% and 0.10%, numerous infiltrates were found in corneas with abscesses. On the other hand, animals treated with 0.3% formulation showed no recurrence of keratitis in any eye over 14 d study period. Therefore, 0.3% vancomycin ointment was suggested to be adequate and effective to resolve corneal MRSA keratitis.

Though considerable effort is being put into research to improve efficacy, still there is a need to overcome certain drawbacks associated with conventional formulations. The above mentioned formulations: emulsion, suspension, and ointment are known to cause ocular adverse effects such as irritation, redness of eye and interference with vision. Also, chronic administration may increase systemic API availability which may lead to severe systemic complications<sup>[38-40]</sup>. Formulations with preservatives also induce adverse reactions upon systemic absorption<sup>[41,42]</sup>. Therefore, to overcome formulation based adverse effects and to deliver therapeutic amounts of drug in ocular tissues, research is now being focused on exploring and developing other novel strategies of ocular drug delivery. In the following sections, we have discussed about the recent developments made in nanotechnology and controlled release devices in past decade to improve ocular drug delivery.

## NOVEL OCULAR DRUG DELIVERY SYSTEMS

### Nanotechnology based ocular drug delivery

In a last few decades, many approaches have been utilized for the treatment of ocular diseases. Nanotechnology based ophthalmic formulations are one of the approaches which is currently being pursued for both anterior, as well as posterior segment drug delivery. Nanotechnology based systems with an appropriate particle size can be designed to ensure low irritation, adequate bioavailability, and ocular tissue compatibility. Several nanocarriers, such as nanoparticles, nanosuspensions, liposomes, nanomicelles and dendrimers have been developed for ocular drug delivery (Figure 3). Some of them have shown promising results for improving ocular bioavailability.

### Nanomicelles

Nanomicelles are the most commonly used carrier systems to formulate therapeutic agents in to clear aqueous solutions. In general, these nanomicelles are made with amphiphilic molecules. These molecules may be surfac-




Figure 3 Nanocarriers for ocular drug delivery.


tant or polymeric in nature. Recently, Cholkar *et al.*<sup>[43]</sup> have reviewed in detail about ocular barriers and application of nanomicelles based technology in ocular drug delivery.

Currently, tremendous interest is being shown towards development of nanomicellar formulation based technology for ocular drug delivery. The reasons may be attributed due to their high drug encapsulation capability, ease of preparation, small size, and hydrophilic nanomicellar corona generating aqueous solution. In addition, micellar formulation can enhance the bioavailability of the therapeutic drugs in ocular tissues, suggesting better therapeutic outcomes. So far, several proofs of concept studies have been conducted to investigate the applicability of nanomicelles in ocular drug delivery. For instance, Civiale *et al.*<sup>[44]</sup> developed dexamethasone loaded nanomicelles by employing copolymers of polyhydroxyethylaspartamide [PHEAC(16)] and pegylated PHEAC(16) for anterior segment delivery. *In vivo* dexamethasone concentration time profiles were studied and determined in rabbits with aqueous humor sampling. Results showed that dexamethasone loaded PHEA micelles have higher ocular bioavailability relative to dexamethasone suspension. The area under the curve for dexamethasone micellar formulation was 40% higher than that of control suspension. Results suggest that nanomicellar formulations are a viable option for topical ocular delivery of small molecules. Researchers have also utilized nanomicelles for ocular gene delivery. In a study, Liaw *et al.*<sup>[45]</sup> made attempts to deliver genes by topical drop administration to cornea. Copolymer, poly (ethylene oxide)-poly (propylene oxide)-poly (ethylene oxide) (PEO-PPO-PEO) was used to develop micelles as a vehicle for gene delivery. This polymeric system efficiently transferred plasmid DNA with *LacZ* gene in rabbit and mice ocular tissues. Results were promising and indicated the potential application of copolymers in DNA transfer. Further studies were conducted with the copolymer to deliver two cornea specific promoters, *i.e.*, keratin 12 (K12) and keratocan. Transgene expression was quantified with  $\beta$ -Gal activity. Significant elevated levels were quantified following six doses of eye drop of pK12-Lac Z-PM three times a day in both mouse and rabbit corneas. The probable mechanism of transfection was endocytosis and particle size dependent paracellular transport of polymeric micelles<sup>[46]</sup>.

Several attempts are also being made to utilize nanomicelles for the posterior ocular drug delivery. Recently, the authors have made a significant stride to deliver thera-

peutic drugs to the posterior ocular tissues with the aid of topical drops of mixed nanomicellar formulations. To bolster the hypothesis that the nanomicelles can deliver the drug to the posterior ocular tissues, *in vivo* studies were carried out in rabbits using voclosporin loaded nanomicelles<sup>[43]</sup>. Interestingly, the nanomicelle formulations were able to efficiently traverse ocular tissues and deliver drug to back of the eye tissues. Ocular tolerability of nanomicelles was evaluated against Restasis<sup>®</sup> as control in New Zealand White (NZW) rabbits. A detailed 72 h study with Hackett-McDonald scoring with microscopic ocular examination was included for two voclosporin (0.02% and 0.2%) micellar and Restasis<sup>®</sup> formulations. Post 1 h-topical drop administration of Restasis<sup>®</sup> highest ocular irritation was observed relative to two micellar voclosporin formulations. It was demonstrated that the novel mixed nanomicellar formulations were well tolerated and induced markedly low irritation than Restasis<sup>®</sup>. Further, authors also prepared dexamethasone and rapamycin mixed nanomicellar formulations at a concentration of 0.1 and 0.2 wt%, respectively. Ocular tissue distribution studies with single drop instillation showed that nanomicellar formulation encapsulating voclosporin, dexamethasone and rapamycin was able to deliver therapeutic concentrations of drug to back of the eye tissues post topical drop instillation. These studies suggest that small size, hydrophilic nanomicellar corona help to evade ocular barriers and deliver drug cargo to posterior ocular tissues. A non-corneal pathway of drug delivery has been hypothesized for back of the eye drug delivery. Ideta *et al.*<sup>[47]</sup> made attempts to deliver fluorescein isothiocyanate-labeled poly-L-lysine [FITC-P(Lys)] to back of the eye tissues *via* intravenous drug administration to treat back of the eye tissue neovascularization. *In vivo* studies with unformulated FITC-P(Lys) resulted in death of animals post 1 h of administration. On the contrary encapsulating the FITC-P(Lys) in polyethylene glycol-block-poly- $\alpha$ , $\beta$ -aspartic acid micelles resulted in no death. This indicates no free drug was available in nanomicellar formulation. Micellar formulation showed a  $C_{max}$  at 4 h in retina-choroid and drug was detected up to 7 d following single intravenous administration. Prolonged micellar circulation was achieved by controlling polymer to drug charge ratios. Authors speculated that longer systemic micellar circulation may aid in enhanced permeation and retention (EPR) effect at neovascularization site. Micellar constructs were observed to selectively accumulate at the pathologic neovascular site to a greater extent than in normal tissues.

In another study, Ideta *et al.*<sup>[48]</sup> made attempts to encapsulate dendritic photosensitizer (DP) in PEG-b-P(Lys) micellar construct for the treatment of exudative AMD with photodynamic therapy. *In vitro* cytotoxicity studies were performed under dark and light irradiation for DP alone and DP loaded polyionic complex (PIC) micelles to be more cytotoxic in light irradiated conditions. This higher cytotoxic effect of polymeric ion complex micelles under light irradiation was utilized for the treatment of exudative AMD. Photocoagulation was induced in rat eye. DP



**Figure 4** Intraocular pressure in normotensive rabbit eyes after topical instillation of melatonin (MEL). <sup>b</sup> $P < 0.01$  vs melatonin; <sup>d</sup> $P < 0.001$  vs RGP-MEL1. Reproduced with permission from Musumeci *et al.*<sup>[61]</sup>. IOP: Intraocular pressure.

loaded PIC micelles were administered by intravenous injection and DP accumulation in choroidal neovascular site was observed. Application of mild laser light treatment destroyed/choked the abnormal vasculature. This new technology prevents further drug leakage. Histological studies revealed accumulation of PIC micelles at ocular lesion site. Reason may be attributed due to EPR effect. Administered free DP was eliminated within 24 h. On the other hand, PIC micelles encapsulated DP were detected after 24 h indicating micellar construct accumulation at lesion site with slow cell uptake. A reduction in fluorescence was observed post 25 min intravenous administration of DP loaded PIC micelles, due to choking of abnormal vasculature. Hypofluorescence of DP micelles was increasing with time indicating increased vascular choking. Normal endothelial cell destruction was not observed, possibly due to lower DP accumulation. Results suggest that small size and hydrophilic negatively charged micellar corona resulted in considerable EPR effect. This resulted in selective drug accumulation in the choroidal neovascular tissues with minimal/no drug induced adverse effects on normal cells.

Ocular research is currently focused to non-invasively deliver therapeutic levels of drugs to both anterior and posterior ocular segments. Advent of nanomicellar technology to delivery drugs in a non-invasive route, topical drop, is gaining interest. Due to their extremely small size and hydrophilic corona, nanomicelles may be retained in systemic circulation for longer time and accumulate at the diseased tissue *via* EPR effect. Thereby, non-specific drug accumulation in to normal tissues may be minimized. Proper selection of surfactant/polymer and engineering technique may aid in delivery of drugs to both anterior and posterior eye segments.

### Nanoparticles

Nanoparticles are colloidal carriers with a size range of

10 to 1000 nm. For ophthalmic delivery, nanoparticles are generally composed of lipids, proteins, natural or synthetic polymers such as albumin, sodium alginate, chitosan, poly (lactide-co-glycolide) (PLGA), polylactic acid (PLA) and polycaprolactone. Drug loaded nanoparticles can be nanocapsules or nanospheres (Figure 3). In nanocapsules, drug is enclosed inside the polymeric shell while in nanospheres; drug is uniformly distributed throughout polymeric matrix. From past few decades, nanoparticles have gained attention for ocular drug delivery and several researchers have made attempts to develop drug loaded nanoparticles for delivery to both anterior and posterior ocular tissues (Table 1)<sup>[49-58]</sup>.

Nanoparticles represents a promising candidate for ocular drug delivery because of small size leading to low irritation and sustained release property avoiding frequent administration. However, like aqueous solutions, nanoparticles may be eliminated rapidly from precorneal pocket. Hence, for topical administration nanoparticles with mucoadhesive properties have been developed to improve precorneal residence time<sup>[59]</sup>. Polyethylene glycol (PEG), chitosan and hyaluronic acid are commonly employed to improve precorneal residence time of nanoparticles.

Chitosan coating is most widely explored for improving precorneal residence of nanoparticles. The chitosan is positively charged and hence it binds to negatively charged corneal surface and thereby improves precorneal residence and decreases clearance. For instance, natamycin loaded chitosan/lecithin nanoparticles exhibited high ocular bioavailability at reduced dose and dosing frequency in rabbit eye compared to marketed suspension. Following topical administration, the concentration-time curve (AUC) (0-∞) was increased up to 1.47 fold and clearance was decreased up to 7.40 fold in case of chitosan/lecithin nanoparticles compared to marketed suspension<sup>[60]</sup>. In another study, Musumeci *et al.*<sup>[61]</sup> reported that melatonin loaded PLGA-PEG nanoparticles were most effective and demonstrated significant intraocular pressure (IOP) lowering effect compared with melatonin loaded PLGA nanoparticles and aqueous solution of equivalent concentration in the rabbit eye (Figure 4). It was speculated that the reduced zeta potential of nanoparticles fabricated from PLGA-PEG than the PLGA allowed better and longer interaction between the nanoparticles and eye surface leading to higher hypotensive effect for prolonged period.

Nanoparticles have also been successfully employed as an alternative strategy for long term drug delivery to the posterior segment ocular tissues. For posterior segment delivery, disposition of nanoparticles depends on the size and surface property. Following, periocular administration in to Sprague-Dawley rats, 20 nm particles were cleared rapidly from periocular tissues. The rapid clearance can be due to removal by conjunctival, episcleral or other periocular circulatory systems. On the other hand, particles in the range of 200-2000 nm were

**Table 1** Summary of recent developments with nanoparticles as ocular drug delivery vehicles

Drug	Polymer	Features
Carboplatin	CH, SA	Carboplatin loaded NPs demonstrated elevated and sustained anti-proliferative activity in a retinoblastoma cell line (Y-79), with IC <sub>50</sub> of 0.56 and 0.004 µg/mL for free carboplatin and carboplatin loaded NPs, respectively <sup>[49]</sup>
5-FU	CH, SA	CH coated SA-CH nanoparticles (CH-SA-CH NPs) loaded with 5-FU showed significantly higher concentration of 5-FU in aqueous humor as compared to SA-CH 5-FU loaded NPs and 5-FU solution. The higher C <sub>max</sub> was achieved in case of CH-SA-CH NPs (24.67 µg/mL) compared to 5-FU solution (6.14 µg/mL) <sup>[50]</sup>
Sparfloxacin	PLGA	After topical application, sparfloxacin-loaded nanoparticles were retained for a longer duration on the corneal surface as compared to an aqueous solution, which was drained rapidly from the corneal surface. Also, <i>in vitro</i> release studies revealed an extended release of sparfloxacin <sup>[51]</sup>
BT	Sodium alginate	BT-loaded nanoparticles provided prolong drug release over a period of 8 h after topical instillation to albino rabbits <sup>[52]</sup>
Levofloxacin	PLGA	The nanosuspensions was retained for the longer time on rabbit eye surface and drained out slowly compared to marketed formulation. Results of <i>ex-vivo</i> transcorneal permeation study across excised goat cornea revealed that levofloxacin from the marketed formulation was permeated 36.9% in 4 h whereas levofloxacin from PLGA nanoparticles was permeated 47.43% in 4 h across cornea <sup>[53]</sup>
DS	PLGA	An extended DS release was observed from the nanoparticles under <i>in vitro</i> conditions. The developed polymer nanoparticles formulation was non-irritant to cornea, iris, and conjunctiva for as long as 24 h after application <sup>[54]</sup>
Pilocarpine	PLGA	The <i>in vivo</i> miosis studies showed that the duration of miotic response increased by 40% for the nanoparticles compared to the eye drops <sup>[55]</sup>
Gatifloxacin/ Prednisolone	Eudragit RS 100 and RL 100, coating with hyaluronic acid	<i>In vitro</i> release studies revealed prolonged drug release compared to the free drugs with no burst effect. Nanoparticles formulation showed better bioavailability of gatifloxacin in rabbit eye with 1.76 fold increase in C <sub>max</sub> of gatifloxacin in the aqueous humor in comparison to the eye drops <sup>[56]</sup>
Cloricromene (AD6)	Eudragit	Nanosuspension enhanced stability of the ester drug for several months as compared to an AD6 aqueous solution <sup>[57]</sup>
Brimonidine Tartrate	Eudragit RS 100 Eudragit RL 100	The AUC (ΔIOP <i>vs</i> time) for the selected nanoparticles formulations were about seven times higher than that of eye drop formulations in rabbit eye <sup>[58]</sup>


CH: Chitosan; SA: Sodium alginate; 5-FU: 5-Fluorouracil; PLGA: Poly (lactide-co-glycolide); IOP: Intraocular pressure; AUC: Area under the curve; BT: Brimonidine tartrate; DS: Diclofenac sodium.

retained at the site of administration for at least two months. Moreover, due to the rapid clearance and fast drug release, small size nanoparticles could not sustain retinal drug level. Therefore, it can be concluded that for prolonged transscleral drug delivery to the back of the eye, nanoparticles with slow drug release and low clearance by blood and lymphatic circulations are suitable drug delivery candidates<sup>[62,63]</sup>.


Following intravitreal injection, nanoparticles migrate through the retinal layers and tend to accumulate in the RPE cells. The PLA nanoparticles were present in rat RPE tissues up to 4 mo following single intravitreal injection which suggest that nanoparticles have great potential for achieving steady and continuous delivery to the back of the eye. Zhang *et al.*<sup>[64]</sup> investigated the pharmacokinetics and tolerance of dexamethasone (DEX) loaded PLGA nanoparticles in rabbits following intravitreal injection. Authors concluded that DEX when encapsulated in nanoparticles exhibited sustained release for 50 d. The constant DEX levels were maintained in vitreous over 30 d with a mean concentration of 3.85 mg/L. Contrary, only trace amounts of DEX being detected on the 7<sup>th</sup> day after injection of DEX solution. These results imply that intravitreal injection of dexamethasone nanoparticles may be employed for sustained delivery of drugs for the treatment of posterior segment eye diseases.

The surface property of nanoparticles is a key factor affecting their distribution from vitreous humor to retinal layers<sup>[65]</sup>. Koo *et al.*<sup>[66]</sup> studied correlation between surface properties of the nanoparticles and their distribution in

the vitreous and retina after intravitreal injection. Heterogeneous polyethyleneimine/glycol chitosan (PEI/GC), human serum albumin (HSA)/GC, and HSA/hyaluronic acid (HA) nanoparticles were prepared by blending two polymers. The value of zeta potential of these nanoparticles were 20.7 ± 3.2, -1.9 ± 4.1 and -23.3 ± 4.4 for PEI/GC, HSA/GC, and HSA/HA nanoparticles, respectively. The nanoparticles were injected into vitreous cavity of Long Evans rats and vitreous/retinal distribution was evaluated by confocal microscopy. Figure 5 shows vitreal and retinal distribution of intravitreally administered heterogeneous nanoparticles. It can be depicted from the Figure 5 that PEI/GC nanoparticles easily penetrated the vitreal barrier and reached at the inner limiting membrane. However, PEI/GC nanoparticles did not penetrate through the physical pores of inner limiting membrane into the deeper retinal layers and also some aggregates were observed in vitreous. Similar to PEI/GC nanoparticles, HSA/GC nanoparticles reached to inner limiting membrane but could not penetrate to the deeper retinal layers which might be due to inhibition of the interaction between HSA and the Müller cells in retina by GC. On the other hand, negatively charged HSA/HA nanoparticles, could penetrate the whole retina structures and reach the outer retinal layers such as the photoreceptor layer and RPE which was attributed to interaction between anionic surface and Müller cells. In another study, HSA-NPs penetrated the whole retina and localized inside the RPE of the normal retina after intravitreal injection in rat eyes. Furthermore, in the laser photocoagulated retina,



**Figure 5 Vitreal and retinal distribution of intravitreally administered.** A: Polyethyleneimine/glycol chitosan heterogeneous nanoparticles; B: Human serum albumin/hyaluronic acid heterogeneous nanoparticles; C: Human serum albumin conjugated nanoparticles 6 h post-injection. Red color = FPR-552 conjugated nanoparticles, blue color = DAPI staining of retinal cell nuclei. VH: Vitreous; RE: Retina; ILM: Inner limiting membrane; INL: Inner nuclear layer; ONL: Outer nuclear layer, respectively. All images were captured at  $\times 10$  magnification. Reproduced with permission from reference Koo *et al*<sup>[66]</sup>.



**Figure 6 Changes in intraocular pressure of rabbits eyes following administration of hydrocortisone solution and nanosuspensions produced by milling and precipitation.** Reproduced with permission from reference Ali *et al*<sup>[70]</sup>. IOP: Intraocular pressure; Hc: Hydrocortisone; NS: Nanosuspension.

HSA-NPs were observed to reach the choroid through the disruption site of the RPE and Bruch’s membrane. Therefore, the anionic HSA-NP could be promising drug delivery carrier for the treatment of AMD which required drug distribution to the choroid region in order to inhibit choroidal neovascularization<sup>[67]</sup>.

### Nanosuspensions

Nanosuspensions are colloidal dispersion of submicron drug particles stabilized by polymer(s) or surfactant(s). It is emerged as promising strategy for delivery of hydrophobic drugs. For ocular delivery, it provides several advantages such as sterilization, ease of eye drop formulation, less irritation, increase precorneal residence time and enhancement in ocular bioavailability of drugs which are insoluble in tear fluid<sup>[68]</sup>. The efficacy of nanosuspensions in improving ocular bioavailability of glucocorticoids has been demonstrated in several research studies.

Glucocorticoids such as prednisolone, dexamethasone and hydrocortisone are widely recommended for the treatment of inflammatory conditions affecting anterior

segment ocular tissues. The current therapy with these drugs requires frequent administration at higher doses which induce cataract formation, glaucoma, and damage optic nerve. Efforts have been made toward improving ocular bioavailability of glucocorticoids by formulating as nanosuspensions. For instance, Kassem *et al*<sup>[69]</sup> compared ocular bioavailability of various glucocorticoids (prednisolone, dexamethasone and hydrocortisone) from nanosuspensions, solutions and microcrystalline suspensions. The formulations were instilled into the lower cul-de-sac of the rabbit eye and intraocular pressure (IOP) was measured at frequent time intervals up to 12 h. The area under percentage increase in IOP *vs* time curve (AUC) values for all the suspensions were higher than that for the respective drug solutions. In addition, higher extent of drug absorption and more intense drug effects were observed for all steroids form nanosuspensions compared with solutions. In another study, Ali *et al*<sup>[70]</sup> compared ocular bioavailability of hydrocortisone (Hc) nanosuspensions prepared by precipitation and milling method with HC solution in rabbits post topical instillation. Nanosuspensions prepared by both the precipitation and milling method achieved significantly higher AUC (0-9 h) values of  $28.06 \pm 4.08$  and  $30.95 \pm 2.2 \mu\text{g/mL}$  than that of HC solution ( $15.86 \pm 2.7 \mu\text{g/mL}$ ). A sustained drug action which was represented in terms of changes in intraocular pressure was maintained up to 9 h for the nanosuspensions compared to 5 h for the drug solution (Figure 6).

From the results of above research studies, it can be concluded that nanosuspensions could be an efficient ophthalmic drug delivery system for delivery of poorly soluble drugs. In addition, nanosuspension can also be incorporated into hydrogels or ocular inserts for achieving sustained drug release for stipulated time period.

### Liposomes

Liposomes are lipid vesicles with one or more phospholipid bilayers enclosing an aqueous core (Figure 3). The size of liposomes usually range from 0.08 to 10.00  $\mu\text{m}$  and based on the size and phospholipid bilayers,

**Table 2** Recent advancements in liposomal ocular drug delivery

Drug	Type of Liposomes	Result
Acetazolamide	Multilamellar, unilamellar	Multilamellar liposomes produced a more significant lowering in IOP in comparison with REVs liposomes <sup>[72]</sup>
Ciprofloxacin	Multilamellar	The mean residence time of ciprofloxacin was three fold higher for the CS-coated liposomes (3.85 h) compared to commercially available eye drops Ciprocin® (1.39 h) <sup>[73]</sup>
Cytochrome C		The cytochrome C loaded freeze-dried liposomes exhibited significant efficacy in retarding the onset and progression of cataract formation in rat eye <sup>[74]</sup>
VIP	Pegylated liposomes	After intravitreal injection, VIP concentration in ocular fluids was 15 times higher for liposomal formulation (155 ± 65 ng/mL) than the solution (10 ± 1 ng/mL), at 24 h <sup>[75]</sup>
Coumarin-6	Multilamellar	After topical administration in mice, the intensity of coumarin-6 in the retina was much higher with PLL modified liposomes <sup>[76]</sup>
Bevacizumab (Avastin)		Vitreous concentration of bevacizumab after 42 d of administration was 16 and 3.3 µg/mL in the eyes for liposomal and non-liposomal bevacizumab, respectively. The AUC (conc vs time) for liposomal bevacizumab was 1.5 fold higher compared with non-liposomal bevacizumab <sup>[77]</sup>
Fluorescence probe (coumarin-6)	Submicron-sized liposomes (ssLips) and multilamellar	After topical instillation of submicron-sized liposomes (ssLips), drug was delivered to the posterior segment ocular tissues including retina <sup>[78]</sup>
Fluconazole		Antifungal activity of fluconazole in liposomal formulation was better than that of fluconazole solution <sup>[79]</sup>
Edaravone	Submicron-sized liposomes	Topical administration of edaravone-loaded ssLips protected retina against light-induced dysfunction in mice eye while there was no marked protection found in the group treated with free edaravone <sup>[80]</sup>
Diclofenac	Multilamellar	Topical administration of diclofenac loaded PVA-R modified liposomes lead to improved retinal delivery in rabbit eye. Concentration of diclofenac in the retina-choroid was enhanced by 1.8 fold in case of drug loaded PVA-R modified liposome compared to that of the diclofenac solution <sup>[81]</sup>


REVs: Reverse phase evaporation; PLL: Poly-L-lysine; VIP: Vasoactive intestinal peptide; PVA: Polyvinyl alcohol; IOP: Intraocular pressure; AUC: Area under the curve.

liposomes can be classified as small unilamellar vesicles (10-100 nm), large unilamellar vesicles (100-300 nm) and multilamellar vesicles (contains more than one bilayer)<sup>[71]</sup>. For ophthalmic applications, liposomes represent ideal delivery systems due to excellent biocompatibility, cell membrane like structure and ability to encapsulate both hydrophilic and hydrophobic drugs. Liposomes have demonstrated good effectiveness for both anterior and posterior segment ocular delivery in several research studies. Recent advancements in liposomal ocular drug delivery are summarized in Table 2<sup>[72-81]</sup>. In a recent study, for delivery of latanoprost to anterior segment ocular tissues, liposomal formulation was developed by Natarajan *et al.*<sup>[82]</sup>. The single subconjunctival injection of latanoprost/liposomal formulation in rabbit eye produced sustained IOP lowering effect over a period of 50 d with IOP reduction comparable to daily eye drop administration. For drug delivery to anterior segment of the eye, efforts are mainly put toward improving precorneal residence time by incorporating positively charged lipids or mucoadhesive polymer in liposomes. The positively charged liposomes *i.e.*, cationic liposomes have exhibited better efficacy in ocular delivery than negatively charged and neutral liposomes due to binding with negatively charges of corneal surface. Didodecyldimethylammonium bromide, stearylamine, and *N*-[1-(2,3-dioleoyloxy)propyl]-*N,N,N*-trimethylammonium chloride are commonly employed for fabricating cationic liposomes.

Acyclovir loaded cationic and anionic liposomes were prepared by incorporating stearylamine and dicylphosphate (DP), as cationic and anionic charge-inducing agents, respectively. In rabbit eyes, the acyclovir concen-

tration in the cornea at 2.5 h after topical administration of positively charged liposomes was greater than those of negatively charged liposomes and free acyclovir. ACV concentrations in cornea were 253.3 ± 72.0, 1093.3 ± 279.7 and 571.7 ± 105.3 ng/g for ACV solution, ACV loaded positively and negatively charged liposomes, respectively. Also, the extent of ACV absorption through cornea was higher from positively charged liposomes which can be observed from ACV concentrations in aqueous humor at 2.5 h after instillation (Figure 7). The suggested reason was the higher binding of positively charged liposomes with negatively charged corneal surface *via* electrostatic interaction which ultimately lead to an increase of residence time and increase in acyclovir absorption<sup>[83]</sup>. In another study, when Coenzyme Q<sub>10</sub> (CoQ<sub>10</sub>) loaded liposomes was coated with mucoadhesive trimethyl chitosan, there was a 4.8 fold increase in the precorneal residence time in the rabbit eye was observed<sup>[84]</sup>.

For posterior segment delivery, liposomes development is more focused toward improving half-life of drug by lessening clearance from vitreous humor, protecting labile molecules such as peptides and oligonucleotides from degradation and providing sustained drug release<sup>[5,85,86]</sup>. For instance, the vitreal half-life of fluconazole in rabbit eye was increased from 3.08 to 23.40 h after formulating into liposomes<sup>[86]</sup>. In another study, tacrolimus loaded liposomes were developed for the treatment of uveoretinitis. Following single intravitreal administration, tacrolimus vitreous level above 50 ng/mL was sustained for 14 d. The tacrolimus liposomal formulation demonstrated more effectiveness in suppressing



**Figure 7** Acyclovir concentrations in aqueous humor after topical administration of Acyclovir solution and Acyclovir-containing liposomes. <sup>a</sup> $P < 0.05$  vs positively charged liposomes ( $n = 6$ ). Reproduced with permission from reference Law *et al.*<sup>[83]</sup>. ACV: Acyclovir.

uveoretinitis relative to drug alone and there was also reduced toxicity to inner retinal cells<sup>[87]</sup>.

Several liposomal formulations for ocular drug delivery are being exploited, few are in pre-clinical and clinical study stage and few are commercially available. Visudyne<sup>®</sup> and Tears again<sup>®</sup> are the examples of commercially available liposomal formulations for the treatment of ocular diseases. Visudyne<sup>®</sup> (QLT Ophthalmics, Inc., Menlo Park, CA, United States) is a liposomal formulation containing photosensitizer, verteporfin. It is used in photodynamic therapy for subfoveal choroidal neovascularization in age related macular degeneration, presumed ocular histoplasmosis and pathological myopia<sup>[88]</sup>. Tears again<sup>®</sup> (Optima Pharmaceutical GmbH, Germany) is a phospholipid liposomes spray approved for the treatment of the Dry Eye syndrome. In clinical studies, this liposomal spray demonstrated significant advantages when compared with triglyceride-containing eye gel and a balanced salt solution<sup>[89,90]</sup>.

### Dendrimers

Dendrimers are characterized as nanosized, highly branched, star shaped polymeric systems. These branched polymeric systems are available in different molecular weights with terminal end amine, hydroxyl or carboxyl functional group. The terminal functional group may be utilized to conjugate targeting moieties<sup>[91]</sup>. Dendrimers are being employed as carrier systems in drug delivery. Selection of molecular weight, size, surface charge, molecular geometry and functional group are critical to deliver drugs. The highly branched structure of dendrimers allows incorporation of wide range of drugs, hydrophobic as well as hydrophilic. In ocular drug delivery, few promising results were reported with these branched polymeric systems<sup>[4,92,93]</sup>.

Poly (amidoamine) (PAMAM) dendrimers are widely employed in ocular drug delivery<sup>[92]</sup>. Vandamme *et al.*<sup>[94]</sup> demonstrated application of PAMAM dendrimers as

ophthalmic vehicles for delivery of pilocarpine nitrate and tropicamide, for miotic and mydriatic activity. In this study, mean ocular residence time for fluorescein in saline and in PAMAM solutions were studied in rabbit eye. Fluorescein in 0.2% w/v Carbopol solution was used as reference bioadhesive polymer. The mean ocular residence time was significantly higher in case of PAMAM solutions and 0.2% w/v Carbopol solution compared to saline. Therefore, the use of dendrimers could be another option for increasing ocular residence time and therapy enhancing ocular bioavailability and achieving better therapeutic outcomes. For instance, PAMAM dendrimers when co-administrated with pilocarpine nitrate and tropicamide, showed higher miotic and mydriatic activity in albino rabbits<sup>[94]</sup>.

In order to avoid scar tissue formation after glaucoma filtration surgery, conjugates of modified PAMAM dendrimers with glucosamine (DG) and glucosamine 6-sulfate (DGS) were synthesized to exert immunomodulatory and anti-angiogenic activities, respectively. The subconjunctival administration of these modified conjugates in rabbit model of glaucoma filtration surgery have shown significant inhibition of pro-inflammatory and pro-angiogenic responses and consequently reduced scar tissue formation. The results obtained from the experiment indicated that the ocular administration of DG and DGS might be effective and safe in clinical practice in avoiding scar tissue formation post glaucoma filtration surgery<sup>[95]</sup>.

### In-situ gelling systems

*In-situ* hydrogels refer to the polymeric solutions which undergo sol-gel phase transition to form viscoelastic gel in response to environmental stimuli. Gelation can be elicited by changes in temperature, pH and ions or can also be induced by UV irradiation. For ocular delivery, research studies have been more focused toward development of thermosensitive gels which respond to changes in temperature<sup>[96]</sup>. Several thermogelling polymers have been reported for ocular delivery which includes poloxamers, multiblock copolymers made of polycaprolactone, polyethylene glycol, poly (lactide), poly (glycolide), poly (*N*-isopropylacrylamide) and chitosan. These thermosensitive polymers form temperature dependent micellar aggregates which gellify after a further temperature increment due to aggregation or packing<sup>[96,97]</sup>. For drug delivery, these polymers are mixed with drugs in the solution state and solution can be administered which forms an *in situ* gel depot at physiological temperature. These thermosensitive gels demonstrated promising results for enhancing ocular bioavailability for both anterior and posterior segment. Gao *et al.*<sup>[98]</sup> have evaluated suitability of thermosensitive gel made of triblock polymer PLGA-PEG-PLGA (poly-(DL-lactic acid co-glycolic acid)-polyethylene glycol-poly-(DL-lactic acid co-glycolic acid) as a ocular delivery carrier for dexamethasone acetate (DXA). It was formulated as either 0.1% w/v DXA solution or 0.1%, w/v DXA in 20% PLGA-PEG-PLGA *in situ* gel forming solution and administered topically in rabbit eye. Following topical

administration, the  $C_{max}$  of DXA in the anterior chamber was significantly higher for the PLGA-PEG-PLGA solution (125.2  $\mu\text{g}/\text{mL}$ ) relative to the eye drop (17.6  $\pm$  2.18  $\text{ng}/\text{mL}$ ) along with higher AUC values. The increment in both  $C_{max}$  and AUC was approximately 7.00 and 7.98 fold for PLGA-PEG-PLGA *in situ* gel compared to the solution eye drops. These results suggest potentiality of PLGA-PEG-PLGA thermosensitive gel forming solution in enhancing ocular bioavailability.

Rieke *et al*<sup>[99]</sup> have reported applicability of ReGel™ (biodegradable and thermosensitive triblock copolymer consisting of PLGA and PEG, in providing sustained release of a large molecule ovalbumin to the choroid and retina following subconjunctival administration in the rat eye. The ovalbumin concentrations were maintained at measurable levels in the sclera, choroid, and retina of rats over a period of 14 d. These results suggest feasibility of thermosetting gel system in providing sustained delivery of macromolecules to the posterior segment ocular tissues such as choroid and retina. Cross linked poly (*N*-isopropylacrylamide) (PNIPAAm)-poly (ethylene glycol) diacrylate hydrogels were also synthesized for sustained release of macromolecules such as bovine serum albumin (BSA) and immunoglobulin G (IgG)<sup>[100]</sup>. The gel system has provided nearly 3 wk of sustained BSA release under *in vitro* condition. The results of research studies clearly signify the advantages of thermosensitive gels in providing sustained drug release, prolong contact time of drugs with the cornea, less frequency of applications, reduced side effects and higher ocular bioavailability over aqueous drops. In conclusion, the thermosensitive gels may be a viable option for the delivery of drugs for treating chronic ocular diseases.

### Contact lens

Contact lenses are thin, and curved shape plastic disks which are designed to cover the cornea<sup>[101]</sup>. After application, contact lens adheres to the film of tears over the cornea due to the surface tension. Drug loaded contact lens have been developed for ocular delivery of numerous drugs such as  $\beta$ -blockers, antihistamines and antimicrobials. It is postulated that in presence of contact lens, drug molecules have longer residence time in the post-lens tear film which ultimately led to higher drug flux through cornea with less drug inflow into the nasolacrimal duct. Usually, drug is loaded into contact lens by soaking them in drug solutions. These soaked contact lenses demonstrated higher efficiency in delivering drug compared to conventional eye drops. Kim *et al*<sup>[102]</sup> observed much higher bioavailability of dexamethasone (DX) from poly (hydroxyethyl methacrylate) (PHEMA) contact lenses in comparison to eye drops. Indeed, efficient than topical drops, these soaked contact lenses suffers from disadvantages of inadequate drug loading and short term drug release. To overcome these obstacles, particle-laden contact lenses and molecularly imprinted contact lenses have been developed. In particle-laden contact lenses, drug is first entrapped in vesicles such

as liposomes, nanoparticles or microemulsion and then these vesicles are dispersed in the contact lens material. Gulsen *et al*<sup>[103,104]</sup> developed particle-laden contact lenses for ocular delivery of lidocaine. In two different studies, they have prepared particle-laden contact lenses by dispersing lidocaine loaded microemulsion drops or liposome in poly-2-hydroxyethyl methacrylate (p-HEMA) hydrogels. Results of both the studies demonstrated the extended release of lidocaine over a period of 8 d. Indeed, particles-laden contact lenses look promising for extended ocular drug delivery; it needs to be stored in drug saturated solutions to avoid drug loss during storage. The designing of stimuli responsive such as pH or temperature sensitive “smart” particles which can release drug only in the eye could eliminate this problem. The imprinted contact lenses have also showed benefit in terms of both drug loading and drug release<sup>[105]</sup>. It has been demonstrated that soft contact lenses fabricated by the molecular imprinting method have 1.6 times higher timolol loading capacity than the contact lenses prepared by a conventional method and also provided sustained timolol delivery<sup>[106]</sup>. In another study, ketotifen fumarate loaded imprinted lenses have revealed higher tear fluid bioavailability compared to drug soaked lenses or ketotifen fumarate marketed eye drops. The relative bioavailability for the imprinted lenses was 3 times greater than that of non-imprinted lenses. The AUC value of ketotifen fumarate for imprinted lenses, non-imprinted lenses and eye drops were 4365  $\pm$  1070  $\mu\text{g}/\text{h}$  per milliliter, 493  $\pm$  180  $\mu\text{g}/\text{h}$  per milliliter, 46.6  $\pm$  24.5  $\mu\text{g}/\text{h}$  per milliliter, respectively<sup>[107]</sup>. The results clearly demonstrate more effectiveness of imprinted lenses over non-imprinted lenses and eye drops.

### Implants

Intraocular implants are specifically designed to provide localized controlled drug release over an extended period. These devices help in circumventing multiple intraocular injections and associated complications<sup>[108,109]</sup>. Usually for drug delivery to posterior ocular tissues, implants are placed intravitreally by making incision through minor surgery at pars plana which is located posterior to the lens and anterior to the retina. Though implantation is invasive procedure, these devices are gaining interest due to their associated advantages such as sustained drug release, local drug release to diseased ocular tissues in therapeutic levels, reduced side effects and ability to circumvent blood retina barrier<sup>[109,110]</sup>. Several implantable devices have been developed for ocular drug delivery especially for the treatment of chronic vitreoretinal diseases.

Ocular implants are available as biodegradable and non-biodegradable drug releasing devices. Non-biodegradable implants offer long-lasting release by achieving near zero order release kinetics<sup>[110]</sup>. Polymers such as polyvinyl alcohol (PVA), ethylene vinyl acetate (EVA), and polysulfone capillary fiber (PCF) are being employed for fabricating non-biodegradable implants<sup>[108]</sup>. Vitrasert® and Retisert® are the examples of marketed non-biodegrad-

able implants.

Vitrasert® (Bausch and Lomb Inc., Rochester, NY, United States) is a controlled-release intraocular implant of ganciclovir approved by Food and Drug Administration (FDA) for the treatment of acquired immune deficiency syndrome-associated cytomegalovirus retinitis. It is composed of a ganciclovir tablet of 4.5 mg surrounded by PVA/EVA that slowly release the drug over an extended period of 5-8 mo. The device provides long term sustained release without systemic toxicity at reduced cost<sup>[108,110,111]</sup>. Retisert® (Bausch and Lomb Inc., Rochester, NY, United States) is approved by FDA for the treatment of chronic uveitis which affects the posterior segment of the eye. It is the first marketed silicone laminated PVA implant. It provides sustained release of fluocinolone acetonide up to 3 years. The implant had effectively controlled inflammation, reduced uveitis recurrences and improved vision acuity. The associated side effects are cataracts and elevated IOP<sup>[110-113]</sup>. Long term drug release may be achieved with these non-biodegradable implants but are associated with certain short comes. These devices have to be surgically implanted and removed after drug depletion, which makes the treatment expensive and patient non-compliance. Also, adverse events such as endophthalmitis, pseudoendophthalmitis, vitreous haze and hemorrhage, cataract development and retinal detachment limit their applications.

Another category of ocular implant includes biodegradable implants. These implants are gaining much attention and are being studied at large due to their biocompatible property and sustained drug release properties. Because of biodegradable nature, these implants are not required to be surgically removed which signify a distinctive advantage over the non-biodegradable implants. Polylactic acid (PLA), polyglycolic acid (PGA), PLGA, and polycaprolactones are the most commonly used polymers for the fabrication of biodegradable implants<sup>[108]</sup>. Examples of biodegradable implants for ocular delivery include Surodex™ and Ozurdex® which are designed for the sustained delivery of dexamethasone for the treatment of intraocular inflammation and macular edema (ME), respectively<sup>[110]</sup>. Surodex™ (Allergan, Inc., Irvine, CA, United States) composes PLGA and hydroxypropyl methylcellulose enclosing dexamethasone. The implant is inserted in the anterior chamber of eye to control post-operative inflammation in cataract patients. It provides sustained dexamethasone release for a period of 7-10 d with improved anti-inflammatory effect comparable to topical steroid administration<sup>[110]</sup>.

Ozurdex® (Allergan Inc., Irvine, CA, United States) is another biocompatible and biodegradable intravitreal implant. It was approved by FDA in June 2009 for the treatment of macular edema. It employs Allergan's NOVADUR® technology for delivering dexamethasone. The NOVADUR® system contains a PLGA polymer matrix which degrades slowly to lactic acid and glycolic acid allowing prolonged release of dexamethasone up to 6 mo. Randomized clinical trials have demonstrated its potency

in reducing vision loss and improving vision acuity in eyes with macular edema associated with branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO). Also, clinical studies with Ozurdex® for treatment of diabetic retinopathy, and Irvine-Gass syndrome proved it as a promising treatment and drug delivery candidate<sup>[110]</sup>.

### Microneedles

Microneedle based technique is an emerging and minimally invasive mode of drug delivery to posterior ocular tissues. This technique may provide efficient treatment strategy for vision threatening posterior ocular diseases such as age related macular degeneration, diabetic retinopathy and posterior uveitis. This new microneedle based administration strategy may reduce the risk and complications associated with intravitreal injections such as retinal detachment, hemorrhage, cataract, endophthalmitis and pseudoendophthalmitis. Moreover, this strategy may help to circumvent blood retinal barrier and deliver therapeutic drug levels to retina/choroid. Microneedles are custom designed to penetrate only hundreds of microns into sclera, so that damage to deeper ocular tissues may be avoided. These needles help to deposit drug or carrier system into sclera or into the narrow space present between sclera and choroid called "suprachoroidal space" (SCS). Puncturing of sclera and depositing drug solution or carrier systems in sclera or SCS may facilitate diffusion of drug into deeper ocular tissues, choroid and neural retina<sup>[114]</sup>. For intraocular delivery of drugs Jason *et al.* investigated the application of microneedles surface coated with drugs<sup>[115]</sup>. Cadaver eyes were used to evaluate the role and scleral penetration of microneedle and intrascleral dissolution of microneedle surface coated drug (sulfurhodamine). Results demonstrated that surface coated drug was rapidly dissolved in scleral tissue indicating high scleral sulfurhodamine deposition within microneedle hole. In another study, Jiang *et al.*<sup>[116]</sup> made attempts to evaluate the performance of microneedles to infuse drug solutions, nanoparticles and microparticles into scleral tissues. By use of microneedles, authors were able to infuse approximately 10-35 µL of fluid in to tissues. Nanoparticles suspensions and microparticles were also delivered into sclera by microneedles however; microparticles were delivered only in the presence of collagenase spreading enzymes and hyaluronidase. Study demonstrated that hollow microneedles may be employed for scleral infusion of drug or micro/nanoparticles with minimal invasive route.

Further, in another study Patel *et al.*<sup>[117]</sup> made attempts to deliver drug solution, nanoparticles and microparticles in the SCS of rabbit, pig, and cadaver eyes with microneedles. Authors hypothesized that microneedle based minimally invasive strategy may help to deliver high level of both drug and nanocarriers to retinal tissues from SCS. Parameters for suprachoroidal delivery with microneedles such as microneedle length, pressure, and particle size were studied and optimized. Results demon-

strated the strategy to be safe, minimally invasive and may sustain drug release. But, the study did not provide any evidence of drug reaching the inner retinal tissues from SCS. Same group made further attempts to study *in vivo* pharmacokinetics of SCS deposited solution/suspension post microneedle infusion. Results demonstrated that microneedle may provide a safe, reliable and targeted approach to chorio-retinal tissues<sup>[117]</sup>.

## CONCLUSION

Drug delivery to targeted ocular tissues has been a major challenge to ocular scientist, for decades. Administration of drug solutions as topical drop with conventional formulations was associated with certain drawbacks which initiated the introduction of different carrier systems for ocular delivery. Tremendous efforts are being put into ocular research toward the development of safe and patient compliant novel drug delivery strategies. Currently, researchers are thriving hard to improve *in vivo* performance of conventional formulations. On the other hand, advent of nanotechnology, new techniques, devices and their applications in drug delivery is developing immense interest to ocular scientists. Drug molecules are being encapsulated into nanosized carrier systems or devices and are being delivered by invasive/non-invasive or minimally invasive mode of drug administration. Several nanotechnology based carrier systems are being developed and studied at large such as nanoparticles, liposomes, nanomicelles, nanosuspensions and dendrimers. Few of these are commercially manufactured at large scale and are applied clinically. Nanotechnology is benefiting the patient body by minimizing the drug induced toxicities and vision loss. Also, these nanocarriers/devices sustain drug release; improve specificity, when targeting moieties are used, and help to reduce the dosing frequency. However, there is still need of developing a carrier system which could reach targeted ocular tissue, including back of the eye tissues, post non-invasive mode of drug administration. With the current pace of ocular research and efforts being made and put in, it is expected to result in a topical drop formulation that retains high precorneal residence time, avoids non-specific drug tissue accumulation and deliver therapeutic drug levels into targeted ocular tissue (both anterior and posterior). In near future, this delivery system may replace invasive mode of drug administration to back of the eye such as periocular and intravitreal injection.

## REFERENCES

- 1 **Bourlais CL**, Acar L, Zia H, Sado PA, Needham T, Leverage R. Ophthalmic drug delivery systems--recent advances. *Prog Retin Eye Res* 1998; **17**: 33-58 [PMID: 9537794 DOI: 10.1016/S1350-9462(97)00002-5]
- 2 **Gulsen D**, Chauhan A. Ophthalmic drug delivery through contact lenses. *Invest Ophthalmol Vis Sci* 2004; **45**: 2342-2347 [PMID: 15223815 DOI: 10.1167/iovs.03-0959]
- 3 **Gaudana R**, Ananthula HK, Parenky A, Mitra AK. Ocular drug delivery. *AAPS J* 2010; **12**: 348-360 [PMID: 20437123 DOI: 10.1208/s12248-010-9183-3]
- 4 **Gaudana R**, Jwala J, Boddu SH, Mitra AK. Recent perspectives in ocular drug delivery. *Pharm Res* 2009; **26**: 1197-1216 [PMID: 18758924 DOI: 10.1007/s11095-008-9694-0]
- 5 **Bochot A**, Fattal E. Liposomes for intravitreal drug delivery: a state of the art. *J Control Release* 2012; **161**: 628-634 [PMID: 22289436 DOI: 10.1016/j.jconrel.2012.01.019]
- 6 **Kim SH**, Lutz RJ, Wang NS, Robinson MR. Transport barriers in transscleral drug delivery for retinal diseases. *Ophthalmic Res* 2007; **39**: 244-254 [PMID: 17851264 DOI: 10.1159/000108117]
- 7 **Lee SJ**, He W, Robinson SB, Robinson MR, Csaky KG, Kim H. Evaluation of clearance mechanisms with transscleral drug delivery. *Invest Ophthalmol Vis Sci* 2010; **51**: 5205-5212 [PMID: 20484583 DOI: 10.1167/iovs.10-5337]
- 8 **Schoenwald RD**. Ocular drug delivery. Pharmacokinetic considerations. *Clin Pharmacokinet* 1990; **18**: 255-269 [PMID: 2182264 DOI: 10.2165/00003088-199018040-00001]
- 9 **Vaka SR**, Sammeta SM, Day LB, Murthy SN. Transcorneal iontophoresis for delivery of ciprofloxacin hydrochloride. *Curr Eye Res* 2008; **33**: 661-667 [PMID: 18696341 DOI: 10.1080/02713680802270945]
- 10 **Tirucherai GS**, Dias C, Mitra AK. Corneal permeation of ganciclovir: mechanism of ganciclovir permeation enhancement by acyl ester prodrug design. *J Ocul Pharmacol Ther* 2002; **18**: 535-548 [PMID: 12537680 DOI: 10.1089/108076802321021081]
- 11 **Gunda S**, Hariharan S, Mitra AK. Corneal absorption and anterior chamber pharmacokinetics of dipeptide monoester prodrugs of ganciclovir (GCV): in vivo comparative evaluation of these prodrugs with Val-GCV and GCV in rabbits. *J Ocul Pharmacol Ther* 2006; **22**: 465-476 [PMID: 17238815 DOI: 10.1089/jop.2006.22.465]
- 12 **Gallarate M**, Chirio D, Bussano R, Peira E, Battaglia L, Baratta F, Trotta M. Development of O/W nanoemulsions for ophthalmic administration of timolol. *Int J Pharm* 2013; **440**: 126-134 [PMID: 23078859 DOI: 10.1016/j.ijpharm.2012.10.015]
- 13 **Tirucherai GS**, Mitra AK. Effect of hydroxypropyl beta cyclodextrin complexation on aqueous solubility, stability, and corneal permeation of acyl ester prodrugs of ganciclovir. *AAPS PharmSciTech* 2003; **4**: E45 [PMID: 14621977 DOI: 10.1208/pt040345]
- 14 **Vulovic N**, Primorac M, Stupar M, Brown MW, Ford JL. Some studies on the preservation of indometacin suspensions intended for ophthalmic use. *Pharmazie* 1990; **45**: 678-679 [PMID: 2284311]
- 15 **Meseguer G**, Buri P, Plazonnet B, Rozier A, Gurny R. Gamma scintigraphic comparison of eyedrops containing pilocarpine in healthy volunteers. *J Ocul Pharmacol Ther* 1996; **12**: 481-488 [PMID: 8951684 DOI: 10.1089/jop.1996.12.481]
- 16 **Gebhardt BM**, Varnell ED, Kaufman HE. Cyclosporine in collagen particles: corneal penetration and suppression of allograft rejection. *J Ocul Pharmacol Ther* 1995; **11**: 509-517 [PMID: 8574814 DOI: 10.1089/jop.1995.11.509]
- 17 **Saettone MF**, Chetoni P, Cerbai R, Mazzanti G, Braghiroli L. Evaluation of ocular permeation enhancers: in vitro effects on corneal transport of four beta-blockers, and in vitro/in vivo toxic activity. *Int J Pharm* 1996; **142**: 103-113 [DOI: 10.1016/0378-5173(96)04663-7]
- 18 **van der Bijl P**, van Eyk AD, Meyer D. Effects of three penetration enhancers on transcorneal permeation of cyclosporine. *Cornea* 2001; **20**: 505-508 [PMID: 11413407 DOI: 10.1097/00003226-200107000-00013]
- 19 **Burgalassi S**, Chetoni P, Monti D, Saettone MF. Cytotoxicity of potential ocular permeation enhancers evaluated on rabbit and human corneal epithelial cell lines. *Toxicol Lett* 2001; **122**: 1-8 [PMID: 11397552 DOI: 10.1016/S0378-4274(01)00261-2]
- 20 **Keister JC**, Cooper ER, Missel PJ, Lang JC, Hager DF. Limits on optimizing ocular drug delivery. *J Pharm Sci* 1991; **80**:

- 50-53 [PMID: 2013850 DOI: 10.1002/jps.2600800113]
- 21 **Hornof MD**, Bernkop-Schnürch A. In vitro evaluation of the permeation enhancing effect of polycarbophil-cysteine conjugates on the cornea of rabbits. *J Pharm Sci* 2002; **91**: 2588-2592 [PMID: 12434402 DOI: 10.1002/jps.10258]
  - 22 **Kurz D**, Ciulla TA. Novel approaches for retinal drug delivery. *Ophthalmol Clin North Am* 2002; **15**: 405-410 [PMID: 12434490 DOI: 10.1016/S0896-1549(02)00034-2]
  - 23 **Cholkar K**, Patel SP, Vadlapudi AD, Mitra AK. Novel strategies for anterior segment ocular drug delivery. *J Ocul Pharmacol Ther* 2013; **29**: 106-123 [PMID: 23215539 DOI: 10.1089/jop.2012.0200]
  - 24 **Mannermaa E**, Vellonen KS, Urtti A. Drug transport in corneal epithelium and blood-retina barrier: emerging role of transporters in ocular pharmacokinetics. *Adv Drug Deliv Rev* 2006; **58**: 1136-1163 [PMID: 17081648 DOI: 10.1016/j.addr.2006.07.024]
  - 25 **Shen J**, Gan L, Zhu C, Zhang X, Dong Y, Jiang M, Zhu J, Gan Y. Novel NSAIDs ophthalmic formulation: flurbiprofen axetil emulsion with low irritation and improved anti-inflammation effect. *Int J Pharm* 2011; **412**: 115-122 [PMID: 21440613 DOI: 10.1016/j.ijpharm.2011.03.041]
  - 26 **Vandamme TF**. Microemulsions as ocular drug delivery systems: recent developments and future challenges. *Prog Retin Eye Res* 2002; **21**: 15-34 [PMID: 11906809 DOI: 10.1016/S1350-9462(01)00017-9]
  - 27 **Liang H**, Brignole-Baudouin F, Rabinovich-Guilatt L, Mao Z, Riancho L, Faure MO, Warnet JM, Lambert G, Baudouin C. Reduction of quaternary ammonium-induced ocular surface toxicity by emulsions: an in vivo study in rabbits. *Mol Vis* 2008; **14**: 204-216 [PMID: 18347566]
  - 28 **Tajika T**, Isowaki A, Sakaki H. Ocular distribution of difluprednate ophthalmic emulsion 0.05% in rabbits. *J Ocul Pharmacol Ther* 2011; **27**: 43-49 [PMID: 21118027 DOI: 10.1089/jop.2010.0093]
  - 29 **Liu Y**, Lin X, Tang X. Lipid emulsions as a potential delivery system for ocular use of azithromycin. *Drug Dev Ind Pharm* 2009; **35**: 887-896 [PMID: 19466890 DOI: 10.1080/03639040802680271]
  - 30 **Karasawa F**, Ehata T, Okuda T, Satoh T. Propofol injection pain is not alleviated by pretreatment with flurbiprofen axetil, a prodrug of a nonsteroidal antiinflammatory drug. *J Anesth* 2000; **14**: 135-137 [PMID: 14564579 DOI: 10.1007/s005400070020]
  - 31 **Yamaguchi M**, Ueda K, Isowaki A, Ohtori A, Takeuchi H, Ohguro N, Tojo K. Mucoadhesive properties of chitosan-coated ophthalmic lipid emulsion containing indomethacin in tear fluid. *Biol Pharm Bull* 2009; **32**: 1266-1271 [PMID: 19571396 DOI: 10.1248/bpb.32.1266]
  - 32 **Lang J**, Roehrs R, Jani R. Ophthalmic preparations. In Remington: The Science and Practice of Pharmacy, 21st ed. Philadelphia: Lippincott Williams & Wilkins, 2009: 856
  - 33 **Scoper SV**, Kabat AG, Owen GR, Stroman DW, Kabra BP, Faulkner R, Kulshreshtha AK, Rusk C, Bell B, Jamison T, Bernal-Perez LF, Brooks AC, Nguyen VA. Ocular distribution, bactericidal activity and settling characteristics of Tobradex ST ophthalmic suspension compared with Tobradex ophthalmic suspension. *Adv Ther* 2008; **25**: 77-88 [PMID: 18309465 DOI: 10.1007/s12325-008-0019-9]
  - 34 **Kinoshita S**, Awamura S, Oshiden K, Nakamichi N, Suzuki H, Yokoi N. Rebamipide (OPC-12759) in the treatment of dry eye: a randomized, double-masked, multicenter, placebo-controlled phase II study. *Ophthalmology* 2012; **119**: 2471-2478 [PMID: 23009892 DOI: 10.1016/j.ophtha.2012.06.052]
  - 35 **Sasaki H**, Yamamura K, Mukai T, Nishida K, Nakamura J, Nakashima M, Ichikawa M. Enhancement of ocular drug penetration. *Crit Rev Ther Drug Carrier Syst* 1999; **16**: 85-146 [PMID: 10099899 DOI: 10.1615/CritRevTherDrugCarrierSyst.v16.i1.20]
  - 36 **Fukuda M**, Hanazome I, Sasaki K. The intraocular dynamics of vancomycin hydrochloride ophthalmic ointment (TN-011) in rabbits. *J Infect Chemother* 2003; **9**: 93-96 [PMID: 12673416 DOI: 10.1007/s10156-002-0219-1]
  - 37 **Eguchi H**, Shiota H, Oguro S, Kasama T. The inhibitory effect of vancomycin ointment on the manifestation of MRSA keratitis in rabbits. *J Infect Chemother* 2009; **15**: 279-283 [PMID: 19856064 DOI: 10.1007/s10156-009-0708-6]
  - 38 **Gray C**. Systemic toxicity with topical ophthalmic medications in children. *Paediatric and Perinatal Drug Therapy* 2006; **7**: 23-29 [DOI: 10.1185/146300905X75334]
  - 39 **Ishibashi T**, Yokoi N, Kinoshita S. Comparison of the short-term effects on the human corneal surface of topical timolol maleate with and without benzalkonium chloride. *J Glaucoma* 2003; **12**: 486-490 [PMID: 14646684 DOI: 10.1097/00061198-200312000-00008]
  - 40 **Whitson JT**, Ochsner KI, Moster MR, Sullivan EK, Andrew RM, Silver LH, Wells DT, James JE, Bosworth CF, Dickerson JE, Landry TA, Bergamini MV. The safety and intraocular pressure-lowering efficacy of brimonidine tartrate 0.15% preserved with polyquaternium-1. *Ophthalmology* 2006; **113**: 1333-1339 [PMID: 16877072 DOI: 10.1016/j.ophtha.2006.03.025]
  - 41 **Ayaki M**, Yaguchi S, Iwasawa A, Koide R. Cytotoxicity of ophthalmic solutions with and without preservatives to human corneal endothelial cells, epithelial cells and conjunctival epithelial cells. *Clin Experiment Ophthalmol* 2008; **36**: 553-559 [PMID: 18954319 DOI: 10.1111/j.1442-9071.2008.01803.x]
  - 42 **Ayaki M**, Iwasawa A, Yaguchi S, Koide R. Preserved and unpreserved 12 anti-allergic ophthalmic solutions and ocular surface toxicity: in vitro assessment in four cultured corneal and conjunctival epithelial cell lines. *Biocontrol Sci* 2010; **15**: 143-148 [PMID: 21212507 DOI: 10.4265/bio.15.143]
  - 43 **Cholkar K**, Patel A, Vadlapudi DA, Mitra AK. Novel Nanomicellar Formulation Approaches for Anterior and Posterior Segment Ocular Drug Delivery. *Recent Patents on Nanomedicine* 2012; **2**: 82-95 [DOI: 10.2174/1877912311202020082]
  - 44 **Civiale C**, Licciardi M, Cavallaro G, Giammona G, Mazzone MG. Polyhydroxyethylaspartamide-based micelles for ocular drug delivery. *Int J Pharm* 2009; **378**: 177-186 [PMID: 19465101 DOI: 10.1016/j.ijpharm.2009.05.028]
  - 45 **Liaw J**, Chang SF, Hsiao FC. In vivo gene delivery into ocular tissues by eye drops of poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) (PEO-PPO-PEO) polymeric micelles. *Gene Ther* 2001; **8**: 999-1004 [PMID: 11438834 DOI: 10.1038/sj.gt.3301485]
  - 46 **Tong YC**, Chang SF, Liu CY, Kao WW, Huang CH, Liaw J. Eye drop delivery of nano-polymeric micelle formulated genes with cornea-specific promoters. *J Gene Med* 2007; **9**: 956-966 [PMID: 17724775 DOI: 10.1002/jgm.1093]
  - 47 **Ideta R**, Yanagi Y, Tamaki Y, Tasaka F, Harada A, Kataoka K. Effective accumulation of polyion complex micelle to experimental choroidal neovascularization in rats. *FEBS Lett* 2004; **557**: 21-25 [PMID: 14741335 DOI: 10.1016/S0014-5793(03)01315-2]
  - 48 **Ideta R**, Tasaka F, Jang WD, Nishiyama N, Zhang GD, Harada A, Yanagi Y, Tamaki Y, Aida T, Kataoka K. Nanotechnology-based photodynamic therapy for neovascular disease using a supramolecular nanocarrier loaded with a dendritic photosensitizer. *Nano Lett* 2005; **5**: 2426-2431 [PMID: 16351191 DOI: 10.1021/nl051679d]
  - 49 **Parveen S**, Mitra M, Krishnakumar S, Sahoo SK. Enhanced antiproliferative activity of carboplatin-loaded chitosan-alginate nanoparticles in a retinoblastoma cell line. *Acta Biomater* 2010; **6**: 3120-3131 [PMID: 20149903 DOI: 10.1016/j.actbio.2010.02.010]
  - 50 **Nagarwal RC**, Kumar R, Pandit JK. Chitosan coated sodium alginate-chitosan nanoparticles loaded with 5-FU for ocular delivery: in vitro characterization and in vivo study in rabbit eye. *Eur J Pharm Sci* 2012; **47**: 678-685 [PMID: 22922098 DOI: 10.1016/j.ejps.2012.08.008]
  - 51 **Gupta H**, Aqil M, Khar RK, Ali A, Bhatnagar A, Mittal G.

- Sparfloxacin-loaded PLGA nanoparticles for sustained ocular drug delivery. *Nanomedicine* 2010; **6**: 324-333 [PMID: 19857606 DOI: 10.1016/j.nano.2009.10.004]
- 52 **Singh KH**, Shinde UA. Development and Evaluation of Novel Polymeric Nanoparticles of Brimonidine Tartrate. *Curr Drug Deliv* 2010 May 24; Epub ahead of print [PMID: 20497099 DOI: 10.2174/1567210204970992018]
- 53 **Gupta H**, Aqil M, Khar RK, Ali A, Bhatnagar A, Mittal G. Biodegradable levofloxacin nanoparticles for sustained ocular drug delivery. *J Drug Target* 2011; **19**: 409-417 [PMID: 20678034 DOI: 10.3109/1061186X.2010.504268]
- 54 **Agnihotri SM**, Vavia PR. Diclofenac-loaded biopolymeric nanosuspensions for ophthalmic application. *Nanomedicine* 2009; **5**: 90-95 [PMID: 18823824 DOI: 10.1016/j.nano.2008.07.003]
- 55 **Nair KL**, Vidyanand S, James J, Kumar GSV. Pilocarpine-loaded poly(DL-lactic-co-glycolic acid) nanoparticles as potential candidates for controlled drug delivery with enhanced ocular pharmacological response. *J Appl Polym Sci* 2012; **124**: 2030-2036 [DOI: 10.1002/app.35229]
- 56 **Ibrahim HK**, El-Leithy IS, Makky AA. Mucoadhesive nanoparticles as carrier systems for prolonged ocular delivery of gatifloxacin/prednisolone bitherapy. *Mol Pharm* 2010; **7**: 576-585 [PMID: 20163167 DOI: 10.1021/mp900279c]
- 57 **Pignatello R**, Ricupero N, Bucolo C, Maugeri F, Maltese A, Puglisi G. Preparation and characterization of eudragit retard nanosuspensions for the ocular delivery of clorimomene. *AAPS PharmSciTech* 2006; **7**: E27 [PMID: 16584158 DOI: 10.1208/pt070127]
- 58 **Bhagav P**, Upadhyay H, Chandran S. Brimonidine tartrate-eudragit long-acting nanoparticles: formulation, optimization, in vitro and in vivo evaluation. *AAPS PharmSciTech* 2011; **12**: 1087-1101 [PMID: 21879393 DOI: 10.1208/s12249-011-9675-1]
- 59 **Bu HZ**, Gukasyan HJ, Goulet L, Lou XJ, Xiang C, Koudriakova T. Ocular disposition, pharmacokinetics, efficacy and safety of nanoparticle-formulated ophthalmic drugs. *Curr Drug Metab* 2007; **8**: 91-107 [PMID: 17305490 DOI: 10.2174/138920007779815977]
- 60 **Bhatta RS**, Chandasana H, Chhonker YS, Rathi C, Kumar D, Mitra K, Shukla PK. Mucoadhesive nanoparticles for prolonged ocular delivery of natamycin: In vitro and pharmacokinetics studies. *Int J Pharm* 2012; **432**: 105-112 [PMID: 22569234 DOI: 10.1016/j.ijpharm.2012.04.060]
- 61 **Musumeci T**, Bucolo C, Carbone C, Pignatello R, Drago F, Puglisi G. Polymeric nanoparticles augment the ocular hypotensive effect of melatonin in rabbits. *Int J Pharm* 2013; **440**: 135-140 [PMID: 23078856 DOI: 10.1016/j.ijpharm.2012.10.014]
- 62 **Amrite AC**, Kompella UB. Size-dependent disposition of nanoparticles and microparticles following subconjunctival administration. *J Pharm Pharmacol* 2005; **57**: 1555-1563 [PMID: 16354399 DOI: 10.1211/jpp.57.12.0005]
- 63 **Amrite AC**, Edelhauser HF, Singh SR, Kompella UB. Effect of circulation on the disposition and ocular tissue distribution of 20 nm nanoparticles after periocular administration. *Mol Vis* 2008; **14**: 150-160 [PMID: 18334929]
- 64 **Zhang L**, Li Y, Zhang C, Wang Y, Song C. Pharmacokinetics and tolerance study of intravitreal injection of dexamethasone-loaded nanoparticles in rabbits. *Int J Nanomedicine* 2009; **4**: 175-183 [PMID: 19774116 DOI: 10.2147/IJN.S6428]
- 65 **Bourges JL**, Gautier SE, Delie F, Bejjani RA, Jeanny JC, Gurny R, BenEzra D, Behar-Cohen FF. Ocular drug delivery targeting the retina and retinal pigment epithelium using polylactide nanoparticles. *Invest Ophthalmol Vis Sci* 2003; **44**: 3562-3569 [PMID: 12882808 DOI: 10.1167/iovs.02-1068]
- 66 **Koo H**, Moon H, Han H, Na JH, Huh MS, Park JH, Woo SJ, Park KH, Kwon IC, Kim K, Kim H. The movement of self-assembled amphiphilic polymeric nanoparticles in the vitreous and retina after intravitreal injection. *Biomaterials* 2012; **33**: 3485-3493 [PMID: 22322197 DOI: 10.1016/j.biomaterials.2012.01.030]
- 67 **Kim H**, Robinson SB, Csaky KG. Investigating the movement of intravitreal human serum albumin nanoparticles in the vitreous and retina. *Pharm Res* 2009; **26**: 329-337 [PMID: 18958405 DOI: 10.1007/s11095-008-9745-6]
- 68 **Patravale VB**, Date AA, Kulkarni RM. Nanosuspensions: a promising drug delivery strategy. *J Pharm Pharmacol* 2004; **56**: 827-840 [PMID: 15233860 DOI: 10.1211/0022357023691]
- 69 **Kassem MA**, Abdel Rahman AA, Ghorab MM, Ahmed MB, Khalil RM. Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs. *Int J Pharm* 2007; **340**: 126-133 [PMID: 17600645 DOI: 10.1016/j.ijpharm.2007.03.011]
- 70 **Ali HS**, York P, Ali AM, Blagden N. Hydrocortisone nanosuspensions for ophthalmic delivery: A comparative study between microfluidic nanoprecipitation and wet milling. *J Control Release* 2011; **149**: 175-181 [PMID: 20946923 DOI: 10.1016/j.jconrel.2010.10.007]
- 71 **Kaur IP**, Garg A, Singla AK, Aggarwal D. Vesicular systems in ocular drug delivery: an overview. *Int J Pharm* 2004; **269**: 1-14 [PMID: 14698571 DOI: j.ijpharm.2003.09.016]
- 72 **Hathout RM**, Mansour S, Mortada ND, Guinedi AS. Liposomes as an ocular delivery system for acetazolamide: in vitro and in vivo studies. *AAPS PharmSciTech* 2007; **8**: 1 [PMID: 17408209 DOI: 10.1208/pt0801001]
- 73 **Abdelbary G**. Ocular ciprofloxacin hydrochloride mucoadhesive chitosan-coated liposomes. *Pharm Dev Technol* 2011; **16**: 44-56 [PMID: 20025433 DOI: 10.3109/10837450903479988]
- 74 **Zhang J**, Guan P, Wang T, Chang D, Jiang T, Wang S. Freeze-dried liposomes as potential carriers for ocular administration of cytochrome c against selenite cataract formation. *J Pharm Pharmacol* 2009; **61**: 1171-1178 [PMID: 19703366 DOI: 10.1211/jpp/61.09.0006]
- 75 **Lajavardi L**, Bochot A, Camelo S, Goldenberg B, Naud MC, Behar-Cohen F, Fattal E, de Kozak Y. Downregulation of endotoxin-induced uveitis by intravitreal injection of vasoactive intestinal Peptide encapsulated in liposomes. *Invest Ophthalmol Vis Sci* 2007; **48**: 3230-3238 [PMID: 17591893 DOI: 10.1167/iovs.06-1305]
- 76 **Sasaki H**, Karasawa K, Hironaka K, Tahara K, Tozuka Y, Takeuchi H. Retinal drug delivery using eyedrop preparations of poly-L-lysine-modified liposomes. *Eur J Pharm Biopharm* 2013; **83**: 364-369 [PMID: 23153668 DOI: 10.1016/j.ejpb.2012.10.014]
- 77 **Abrishami M**, Zarei-Ghanavati S, Soroush D, Rouhbakhsh M, Jaafari MR, Malaekheh-Nikouei B. Preparation, characterization, and in vivo evaluation of nanoliposomes-encapsulated bevacizumab (avastin) for intravitreal administration. *Retina* 2009; **29**: 699-703 [PMID: 19430280 DOI: 10.1097/IAE.0b013e3181a2f42a]
- 78 **Inokuchi Y**, Hironaka K, Fujisawa T, Tozuka Y, Tsuruma K, Shimazawa M, Takeuchi H, Hara H. Physicochemical properties affecting retinal drug/coumarin-6 delivery from nanocarrier systems via eyedrop administration. *Invest Ophthalmol Vis Sci* 2010; **51**: 3162-3170 [PMID: 20053972 DOI: 10.1167/iovs.09-4697]
- 79 **Habib FS**, Fouad EA, Abdel-Rhman MS, Fathalla D. Liposomes as an ocular delivery system of fluconazole: in-vitro studies. *Acta Ophthalmol* 2010; **88**: 901-904 [PMID: 19681761 DOI: 10.1111/j.1755-3768.2009.01584.x]
- 80 **Shimazaki H**, Hironaka K, Fujisawa T, Tsuruma K, Tozuka Y, Shimazawa M, Takeuchi H, Hara H. Edaravone-loaded liposome eyedrops protect against light-induced retinal damage in mice. *Invest Ophthalmol Vis Sci* 2011; **52**: 7289-7297 [PMID: 21849425 DOI: 10.1167/iovs.11-7983]
- 81 **Fujisawa T**, Miyai H, Hironaka K, Tsukamoto T, Tahara K, Tozuka Y, Ito M, Takeuchi H. Liposomal diclofenac eye drop formulations targeting the retina: formulation stability improvement using surface modification of liposomes. *Int J Pharm* 2012; **436**: 564-567 [PMID: 22828072 DOI: 10.1016/

- j.ijpharm.2012.07.024]
- 82 **Natarajan JV**, Chattopadhyay S, Ang M, Darwitan A, Foo S, Zhen M, Koo M, Wong TT, Venkatraman SS. Sustained release of an anti-glaucoma drug: demonstration of efficacy of a liposomal formulation in the rabbit eye. *PLoS One* 2011; **6**: e24513 [PMID: 21931735 DOI: 10.1371/journal.pone.0024513]
  - 83 **Law SL**, Huang KJ, Chiang CH. Acyclovir-containing liposomes for potential ocular delivery. Corneal penetration and absorption. *J Control Release* 2000; **63**: 135-140 [PMID: 10640587 DOI: 10.1016/S0168-3659(99)00192-3]
  - 84 **Zhang J**, Wang S. Topical use of coenzyme Q10-loaded liposomes coated with trimethyl chitosan: tolerance, precorneal retention and anti-cataract effect. *Int J Pharm* 2009; **372**: 66-75 [PMID: 19437594 DOI: 10.1016/j.ijpharm.2009.01.001]
  - 85 **Alghadyan AA**, Peyman GA, Khoobehi B, Milner S, Liu KR. Liposome-bound cyclosporine: clearance after intravitreal injection. *Int Ophthalmol* 1988; **12**: 109-112 [PMID: 3229899 DOI: 10.1007/BF00137135]
  - 86 **Gupta SK**, Velpandian T, Dhingra N, Jaiswal J. Intravitreal pharmacokinetics of plain and liposome-entrapped fluconazole in rabbit eyes. *J Ocul Pharmacol Ther* 2000; **16**: 511-518 [PMID: 11132898 DOI: 10.1089/jop.2000.16.511]
  - 87 **Zhang R**, He R, Qian J, Guo J, Xue K, Yuan YF. Treatment of experimental autoimmune uveoretinitis with intravitreal injection of tacrolimus (FK506) encapsulated in liposomes. *Invest Ophthalmol Vis Sci* 2010; **51**: 3575-3582 [PMID: 20164461 DOI: 10.1167/iovs.09-4373]
  - 88 **Keam SJ**, Scott LJ, Curran MP. Verteporfin : a review of its use in the management of subfoveal choroidal neovascularisation. *Drugs* 2003; **63**: 2521-2554 [PMID: 14609361 DOI: 10.2165/00003495-200363220-00016]
  - 89 **Dausch D**, Lee S, Dausch S, Kim JC, Schwert G, Michelson W. [Comparative study of treatment of the dry eye syndrome due to disturbances of the tear film lipid layer with lipid-containing tear substitutes]. *Klin Monbl Augenheilkd* 2006; **223**: 974-983 [PMID: 17199193 DOI: 10.1055/s-2006-927266]
  - 90 **Lee S**, Dausch S, Maierhofer G, Dausch D. [A new therapy concept for the treatment of dry eye--the usefulness of phospholipid liposomes]. *Klin Monbl Augenheilkd* 2004; **221**: 825-836 [PMID: 15499517 DOI: 10.1055/s-2004-813715]
  - 91 **Fischer M**, Vögtle F. Dendrimers: From Design to Application-A Progress Report. *Angew Chem Int Ed* 1999; **38**: 884-905 [DOI: 10.1002/(SICI)1521-3773(19990401)38:7%3C884::AID-ANIE884%3E3.0.CO;2-K/abstract]
  - 92 **Abdelkader H**, Alany RG. Controlled and continuous release ocular drug delivery systems: pros and cons. *Curr Drug Deliv* 2012; **9**: 421-430 [PMID: 22640036 DOI: 10.2174/156720112801323125]
  - 93 **Spataro G**, Malecaze F, Turrin CO, Soler V, Duhayon C, Elena PP, Majoral JP, Caminade AM. Designing dendrimers for ocular drug delivery. *Eur J Med Chem* 2010; **45**: 326-334 [PMID: 19889480 DOI: 10.1016/j.ejmech.2009.10.017]
  - 94 **Vandamme TF**, Brobeck L. Poly(amidoamine) dendrimers as ophthalmic vehicles for ocular delivery of pilocarpine nitrate and tropicamide. *J Control Release* 2005; **102**: 23-38 [PMID: 15653131 DOI: 10.1016/j.jconrel.2004.09.015]
  - 95 **Shaunak S**, Thomas S, Gianasi E, Godwin A, Jones E, Teo I, Mireskandari K, Luthert P, Duncan R, Patterson S, Khaw P, Brocchini S. Polyvalent dendrimer glucosamine conjugates prevent scar tissue formation. *Nat Biotechnol* 2004; **22**: 977-984 [PMID: 15258595 DOI: 10.1038/nbt995]
  - 96 **Rajoria G**, Gupta A. In-Situ Gelling System: A Novel Approach for Ocular Drug Delivery. *AJPTR* 2012; **2**: 24-53 Available from: URL: <http://www.scopemed.org/?jft=42&ft=42-1348137747>
  - 97 **Bonacucina G**, Cespi M, Mencarelli G, Giorgioni G, Palmieri GF. Thermosensitive Self-Assembling Block Copolymers as Drug Delivery Systems. *Polymers* 2011; **3**: 779-811 [DOI: 10.3390/polym3020779]
  - 98 **Gao Y**, Sun Y, Ren F, Gao S. PLGA-PEG-PLGA hydrogel for ocular drug delivery of dexamethasone acetate. *Drug Dev Ind Pharm* 2010; **36**: 1131-1138 [PMID: 20334543 DOI: 10.3109/03639041003680826]
  - 99 **Rieke ER**, Amaral J, Becerra SP, Lutz RJ. Sustained subconjunctival protein delivery using a thermosetting gel delivery system. *J Ocul Pharmacol Ther* 2010; **26**: 55-64 [PMID: 20148655 DOI: 10.1089/jop.2009.0059]
  - 100 **Kang Derwent JJ**, Mieler WF. Thermoresponsive hydrogels as a new ocular drug delivery platform to the posterior segment of the eye. *Trans Am Ophthalmol Soc* 2008; **106**: 206-213; discussion 213-214 [PMID: 19277236]
  - 101 **Gupta H**, Aqil M. Contact lenses in ocular therapeutics. *Drug Discov Today* 2012; **17**: 522-527 [PMID: 22305935 DOI: 10.1016/j.drudis.2012.01.014]
  - 102 **Kim J**, Chauhan A. Dexamethasone transport and ocular delivery from poly(hydroxyethyl methacrylate) gels. *Int J Pharm* 2008; **353**: 205-222 [PMID: 18206326 DOI: 10.1016/j.ijpharm.2007.11.049]
  - 103 **Gulsen D**, Li CC, Chauhan A. Dispersion of DMPC liposomes in contact lenses for ophthalmic drug delivery. *Curr Eye Res* 2005; **30**: 1071-1080 [PMID: 16354620 DOI: 10.1080/02713680500346633]
  - 104 **Gulsen D**, Chauhan A. Dispersion of microemulsion drops in HEMA hydrogel: a potential ophthalmic drug delivery vehicle. *Int J Pharm* 2005; **292**: 95-117 [PMID: 15725557 DOI: 10.1016/j.ijpharm.2004.11.033]
  - 105 **White CJ**, Byrne ME. Molecularly imprinted therapeutic contact lenses. *Expert Opin Drug Deliv* 2010; **7**: 765-780 [PMID: 20408742 DOI: 10.1517/17425241003770098]
  - 106 **Hiratani H**, Fujiwara A, Tamiya Y, Mizutani Y, Alvarez-Lorenzo C. Ocular release of timolol from molecularly imprinted soft contact lenses. *Biomaterials* 2005; **26**: 1293-1298 [PMID: 15475059 DOI: 10.1016/j.biomaterials.2004.04.030]
  - 107 **Tieppo A**, White CJ, Paine AC, Voyles ML, McBride MK, Byrne ME. Sustained in vivo release from imprinted therapeutic contact lenses. *J Control Release* 2012; **157**: 391-397 [PMID: 21982900 DOI: 10.1016/j.jconrel.2011.09.087]
  - 108 **Bourges JL**, Bloquel C, Thomas A, Froussart F, Bochot A, Azan F, Gurny R, BenEzra D, Behar-Cohen F. Intraocular implants for extended drug delivery: therapeutic applications. *Adv Drug Deliv Rev* 2006; **58**: 1182-1202 [PMID: 17107737 DOI: 10.1016/j.addr.2006.07.026]
  - 109 **Del Amo EM**, Urtti A. Current and future ophthalmic drug delivery systems. A shift to the posterior segment. *Drug Discov Today* 2008; **13**: 135-143 [PMID: 18275911 DOI: 10.1016/j.drudis.2007.11.002]
  - 110 **Lee SS**, Hughes P, Ross AD, Robinson MR. Biodegradable implants for sustained drug release in the eye. *Pharm Res* 2010; **27**: 2043-2053 [PMID: 20535532 DOI: 10.1007/s11095-010-0159-x]
  - 111 **Choonara YE**, Pillay V, Danckwerts MP, Carmichael TR, du Toit LC. A review of implantable intravitreal drug delivery technologies for the treatment of posterior segment eye diseases. *J Pharm Sci* 2010; **99**: 2219-2239 [PMID: 19894268 DOI: 10.1002/jps.21987]
  - 112 **Mohammad DA**, Sweet BV, Elner SG. Retisert: is the new advance in treatment of uveitis a good one? *Ann Pharmacother* 2007; **41**: 449-454 [PMID: 17341531 DOI: 10.1345/aph.1H540]
  - 113 **Jaffe GJ**, McCallum RM, Branchaud B, Skalak C, Butuner Z, Ashton P. Long-term follow-up results of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis. *Ophthalmology* 2005; **112**: 1192-1198 [PMID: 15921758 DOI: 10.1016/j.ophtha.2005.03.013]
  - 114 **Donnelly RF**, Raj Singh TR, Woolfson AD. Microneedle-based drug delivery systems: microfabrication, drug delivery, and safety. *Drug Deliv* 2010; **17**: 187-207 [PMID: 20297904 DOI: 10.3109/10717541003667798]
  - 115 **Jiang J**, Gill HS, Ghate D, McCarey BE, Patel SR, Edelhofer HF, Prausnitz MR. Coated microneedles for drug delivery to

- the eye. *Invest Ophthalmol Vis Sci* 2007; **48**: 4038-4043 [PMID: 17724185 DOI: 10.1167/iovs.07-0066]
- 116 **Jiang J**, Moore JS, Edelhauser HF, Prausnitz MR. Intrasceral drug delivery to the eye using hollow microneedles. *Pharm Res* 2009; **26**: 395-403 [PMID: 18979189 DOI: 10.1007/s11095-008-9756-3]
- 117 **Patel SR**, Lin AS, Edelhauser HF, Prausnitz MR. Suprachoroidal drug delivery to the back of the eye using hollow microneedles. *Pharm Res* 2011; **28**: 166-176 [PMID: 20857178 DOI: 10.1007/s11095-010-0271-y]

**P- Reviewers** Pan WH, Hsieh MF  
**S- Editor** Zhai HH **L- Editor** A **E- Editor** Lu YJ



**GENERAL INFORMATION**

*World Journal of Pharmacology* (*World J Pharmacol*, *WJP*, online ISSN 2220-3192, DOI: 10.5497) is a peer-reviewed open access (OA) academic journal that aims to guide clinical practice and improve diagnostic and therapeutic skills of clinicians.

**Aim and scope**

*WJP* covers topics concerning neuropsychiatric pharmacology, cerebrovascular pharmacology, geriatric pharmacology, anti-inflammatory and immunological pharmacology, antitumor pharmacology, anti-infective pharmacology, metabolic pharmacology, gastrointestinal and hepatic pharmacology, respiratory pharmacology, blood pharmacology, urinary and reproductive pharmacology, pharmacokinetics and pharmacodynamics, clinical pharmacology, and drug toxicology. The current columns of *WJP* include editorial, frontier, therapeutics advances, field of vision, mini-reviews, review, topic highlight, medical ethics, original articles, case report, clinical case conference (Clinicopathological conference), and autobiography.

We encourage authors to submit their manuscripts to *WJP*. We will give priority to manuscripts that are supported by major national and international foundations and those that are of great basic and clinical significance.

*WJP* is edited and published by Baishideng Publishing Group (BPG). BPG has a strong professional editorial team composed of science editors, language editors and electronic editors. BPG currently publishes 42 OA clinical medical journals, including 41 in English, has a total of 15 471 editorial board members or peer reviewers, and is a world first-class publisher.

**Columns**

The columns in the issues of *WJP* will include: (1) Editorial: The editorial board members are invited to make comments on an important topic in their field in terms of its current research status and future directions to lead the development of this discipline; (2) Frontier: The editorial board members are invited to select a highly cited cutting-edge original paper of his/her own to summarize major findings, the problems that have been resolved and remain to be resolved, and future research directions to help readers understand his/her important academic point of view and future research directions in the field; (3) Diagnostic Advances: The editorial board members are invited to write high-quality diagnostic advances in their field to improve the diagnostic skills of readers. The topic covers general clinical diagnosis, differential diagnosis, pathological diagnosis, laboratory diagnosis, imaging diagnosis, endoscopic diagnosis, biotechnological diagnosis, functional diagnosis, and physical diagnosis; (4) Therapeutics Advances: The editorial board members are invited to write high-quality therapeutic advances in their field to help improve the therapeutic skills of readers. The topic covers medication therapy, psychotherapy, physical therapy, replacement therapy, interventional therapy, minimally invasive therapy, endoscopic therapy, transplantation therapy, and surgical therapy; (5) Field of Vision: The editorial board members are invited to write commentaries on classic articles, hot topic articles, or latest articles to keep readers at the forefront of research and increase their levels of clinical research. Classic articles refer to papers that are included in Web of Knowledge and have received a large number of citations (ranking in the top 1%) after being published for more than years, reflecting the quality and impact of papers. Hot topic articles refer to papers that are included in Web of Knowledge and

have received a large number of citations after being published for no more than 2 years, reflecting cutting-edge trends in scientific research. Latest articles refer to the latest published high-quality papers that are included in PubMed, reflecting the latest research trends. These commentary articles should focus on the status quo of research, the most important research topics, the problems that have now been resolved and remain to be resolved, and future research directions. Basic information about the article to be commented (including authors, article title, journal name, year, volume, and inclusive page numbers); (6) Minireviews: The editorial board members are invited to write short reviews on recent advances and trends in research of molecular biology, genomics, and related cutting-edge technologies to provide readers with the latest knowledge and help improve their diagnostic and therapeutic skills; (7) Review: To make a systematic review to focus on the status quo of research, the most important research topics, the problems that have now been resolved and remain to be resolved, and future research directions; (8) Topic Highlight: The editorial board members are invited to write a series of articles (7-10 articles) to comment and discuss a hot topic to help improve the diagnostic and therapeutic skills of readers; (9) Medical Ethics: The editorial board members are invited to write articles about medical ethics to increase readers' knowledge of medical ethics. The topic covers international ethics guidelines, animal studies, clinical trials, organ transplantation, etc.; (10) Clinical Case Conference or Clinicopathological Conference: The editorial board members are invited to contribute high-quality clinical case conference; (11) Original Articles: To report innovative and original findings in pharmacology; (12) Brief Articles: To briefly report the novel and innovative findings in pharmacology; (13) Meta-Analysis: Covers the systematic review, mixed-treatment comparison, meta-regression, and overview of reviews, in order to summarize a given quantitative effect, e.g., the clinical effectiveness and safety of clinical treatments by combining data from two or more randomized controlled trials, thereby providing more precise and externally valid estimates than those which would stem from each individual dataset if analyzed separately from the others; (14) Case Report: To report a rare or typical case; (15) Letters to the Editor: To discuss and make reply to the contributions published in *WJP*, or to introduce and comment on a controversial issue of general interest; (16) Book Reviews: To introduce and comment on quality monographs of pharmacology; and (17) Autobiography: The editorial board members are invited to write their autobiography to provide readers with stories of success or failure in their scientific research career. The topic covers their basic personal information and information about when they started doing research work, where and how they did research work, what they have achieved, and their lessons from success or failure.

**Name of journal**

*World Journal of Pharmacology*

**ISSN**

ISSN 2220-3192 (online)

**Launch date**

February 9, 2012

**Frequency**

Quarterly

**Editor-in-Chief**

Geoffrey Burnstock, PhD, DSc, FAA, FRCS (Hon), FRCP

## Instructions to authors

(Hon), FmedSci, FRS, Professor, Autonomic Neuroscience Centre, University College Medical School, Royal Free Campus, Rowland Hill Street, London NW3 2PF, United Kingdom

### Editorial office

Jin-Lei Wang, Director  
Xiu-Xia Song, Vice Director  
*World Journal of Pharmacology*  
Room 903, Building D, Ocean International Center,  
No. 62 Dongsihuan Zhonglu, Chaoyang District,  
Beijing 100025, China  
Telephone: +86-10-85381891  
Fax: +86-10-85381893  
E-mail: wjpharmaco@wjnet.com  
<http://www.wjnet.com>

### Publisher

Baishideng Publishing Group Co., Limited  
Flat C, 23/F, Lucky Plaza, 315-321 Lockhart Road,  
Wan Chai, Hong Kong, China  
Telephone: +852-58042046  
Fax: +852-31158812  
E-mail: bpgoffice@wjnet.com  
<http://www.wjnet.com>

### Production center

Beijing Baishideng BioMed Scientific Co., Limited  
Room 903, Building D, Ocean International Center,  
No. 62 Dongsihuan Zhonglu, Chaoyang District,  
Beijing 100025, China  
Telephone: +86-10-85381892  
Fax: +86-10-85381893

### Representative office

USA Office  
8226 Regency Drive,  
Pleasanton, CA 94588-3144, United States

### Instructions to authors

Full instructions are available online at [http://www.wjnet.com/2220-3192/g\\_info\\_20100722180909.htm](http://www.wjnet.com/2220-3192/g_info_20100722180909.htm).

### Indexed and Abstracted in

Digital Object Identifier.

---

## SPECIAL STATEMENT

All articles published in this journal represent the viewpoints of the authors except where indicated otherwise.

### Biostatistical editing

Statistical review is performed after peer review. We invite an expert in Biomedical Statistics to evaluate the statistical method used in the paper, including *t*-test (group or paired comparisons), chi-squared test, Ridit, probit, logit, regression (linear, curvilinear, or stepwise), correlation, analysis of variance, analysis of covariance, *etc.* The reviewing points include: (1) Statistical methods should be described when they are used to verify the results; (2) Whether the statistical techniques are suitable or correct; (3) Only homogeneous data can be averaged. Standard deviations are preferred to standard errors. Give the number of observations and subjects (*n*). Losses in observations, such as drop-outs from the study should be reported; (4) Values such as ED50, LD50, IC50 should have their 95% confidence limits calculated and compared by weighted probit analysis (Bliss and Finney); and (5) The word 'significantly' should be replaced by its synonyms (if it indicates extent) or the *P* value (if it indicates statistical significance).

### Conflict-of-interest statement

In the interests of transparency and to help reviewers assess any potential bias, *WJP* requires authors of all papers to declare any compet-

ing commercial, personal, political, intellectual, or religious interests in relation to the submitted work. Referees are also asked to indicate any potential conflict they might have reviewing a particular paper. Before submitting, authors are suggested to read "Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Ethical Considerations in the Conduct and Reporting of Research: Conflicts of Interest" from International Committee of Medical Journal Editors (ICMJE), which is available at: [http://www.icmje.org/ethical\\_4conflicts.html](http://www.icmje.org/ethical_4conflicts.html).

Sample wording: [Name of individual] has received fees for serving as a speaker, a consultant and an advisory board member for [names of organizations], and has received research funding from [names of organization]. [Name of individual] is an employee of [name of organization]. [Name of individual] owns stocks and shares in [name of organization]. [Name of individual] owns patent [patent identification and brief description].

### Statement of informed consent

Manuscripts should contain a statement to the effect that all human studies have been reviewed by the appropriate ethics committee or it should be stated clearly in the text that all persons gave their informed consent prior to their inclusion in the study. Details that might disclose the identity of the subjects under study should be omitted. Authors should also draw attention to the Code of Ethics of the World Medical Association (Declaration of Helsinki, 1964, as revised in 2004).

### Statement of human and animal rights

When reporting the results from experiments, authors should follow the highest standards and the trial should conform to Good Clinical Practice (for example, US Food and Drug Administration Good Clinical Practice in FDA-Regulated Clinical Trials; UK Medicines Research Council Guidelines for Good Clinical Practice in Clinical Trials) and/or the World Medical Association Declaration of Helsinki. Generally, we suggest authors follow the lead investigator's national standard. If doubt exists whether the research was conducted in accordance with the above standards, the authors must explain the rationale for their approach and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study.

Before submitting, authors should make their study approved by the relevant research ethics committee or institutional review board. If human participants were involved, manuscripts must be accompanied by a statement that the experiments were undertaken with the understanding and appropriate informed consent of each. Any personal item or information will not be published without explicit consents from the involved patients. If experimental animals were used, the materials and methods (experimental procedures) section must clearly indicate that appropriate measures were taken to minimize pain or discomfort, and details of animal care should be provided.

---

## SUBMISSION OF MANUSCRIPTS

Manuscripts should be typed in 1.5 line spacing and 12 pt. Book Antiqua with ample margins. Number all pages consecutively, and start each of the following sections on a new page: Title Page, Abstract, Introduction, Materials and Methods, Results, Discussion, Acknowledgements, References, Tables, Figures, and Figure Legends. Neither the editors nor the publisher are responsible for the opinions expressed by contributors. Manuscripts formally accepted for publication become the permanent property of Baishideng Publishing Group Co., Limited, and may not be reproduced by any means, in whole or in part, without the written permission of both the authors and the publisher. We reserve the right to copyedit and put onto our website accepted manuscripts. Authors should follow the relevant guidelines for the care and use of laboratory animals of their institution or national animal welfare committee. For the sake of transparency in regard to the performance and reporting of clinical trials, we endorse the policy of the ICMJE to refuse to publish papers on clinical trial results if the trial was not recorded in a publicly-accessible registry at its outset. The only register now available, to our knowledge, is <http://www.clinicaltrials.gov> sponsored by the United States National Library of Medicine and we encourage all potential contributors to register with it. However, in the

case that other registers become available you will be duly notified. A letter of recommendation from each author's organization should be provided with the contributed article to ensure the privacy and secrecy of research is protected.

Authors should retain one copy of the text, tables, photographs and illustrations because rejected manuscripts will not be returned to the author(s) and the editors will not be responsible for loss or damage to photographs and illustrations sustained during mailing.

### Online submissions

Manuscripts should be submitted through the Online Submission System at: <http://www.wjgnet.com/esps/>. Authors are highly recommended to consult the ONLINE INSTRUCTIONS TO AUTHORS ([http://www.wjgnet.com/2220-3192/g\\_info\\_20100722180909.htm](http://www.wjgnet.com/2220-3192/g_info_20100722180909.htm)) before attempting to submit online. For assistance, authors encountering problems with the Online Submission System may send an email describing the problem to [wjpharmaco@wjgnet.com](mailto:wjpharmaco@wjgnet.com), or by telephone: +86-10-85381892. If you submit your manuscript online, do not make a postal contribution. Repeated online submission for the same manuscript is strictly prohibited.

## MANUSCRIPT PREPARATION

All contributions should be written in English. All articles must be submitted using word-processing software. All submissions must be typed in 1.5 line spacing and 12 pt. Book Antiqua with ample margins. Style should conform to our house format. Required information for each of the manuscript sections is as follows:

### Title page

**Title:** Title should be less than 12 words.

**Running title:** A short running title of less than 6 words should be provided.

**Authorship:** Authorship credit should be in accordance with the standard proposed by ICMJE, based on (1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; (2) drafting the article or revising it critically for important intellectual content; and (3) final approval of the version to be published. Authors should meet conditions 1, 2, and 3.

**Institution:** Author names should be given first, then the complete name of institution, city, province and postcode. For example, Xu-Chen Zhang, Li-Xin Mei, Department of Pathology, Chengde Medical College, Chengde 067000, Hebei Province, China. One author may be represented from two institutions, for example, George Sgourakis, Department of General, Visceral, and Transplantation Surgery, Essen 45122, Germany; George Sgourakis, 2nd Surgical Department, Korgialenio-Benakio Red Cross Hospital, Athens 15451, Greece

**Author contributions:** The format of this section should be: Author contributions: Wang CL and Liang L contributed equally to this work; Wang CL, Liang L, Fu JF, Zou CC, Hong F and Wu XM designed the research; Wang CL, Zou CC, Hong F and Wu XM performed the research; Xue JZ and Lu JR contributed new reagents/analytic tools; Wang CL, Liang L and Fu JF analyzed the data; and Wang CL, Liang L and Fu JF wrote the paper.

**Supportive foundations:** The complete name and number of supportive foundations should be provided, e.g., Supported by National Natural Science Foundation of China, No. 30224801

**Correspondence to:** Only one corresponding address should be provided. Author names should be given first, then author title, affiliation, the complete name of institution, city, postcode, province, country, and email. All the letters in the email should be in lower case. A space interval should be inserted between country name and email address. For example, Montgomery Bissell, MD, Professor of Medicine, Chief, Liver Center, Gastroenterology Division, Uni-

versity of California, Box 0538, San Francisco, CA 94143, United States. [montgomery.bissell@ucsf.edu](mailto:montgomery.bissell@ucsf.edu)

**Telephone and fax:** Telephone and fax should consist of +, country number, district number and telephone or fax number, e.g., Telephone: +86-10-85381892 Fax: +86-10-85381893

**Peer reviewers:** All articles received are subject to peer review. Normally, three experts are invited for each article. Decision on acceptance is made only when at least two experts recommend publication of an article. All peer-reviewers are acknowledged on Express Submission and Peer-review System website.

### Abstract

There are unstructured abstracts (no less than 200 words) and structured abstracts. The specific requirements for structured abstracts are as follows:

An informative, structured abstract should accompany each manuscript. Abstracts of original contributions should be structured into the following sections: AIM (no more than 20 words; Only the purpose of the study should be included. Please write the Aim in the form of "To investigate/study/..."), METHODS (no less than 140 words for Original Articles; and no less than 80 words for Brief Articles), RESULTS (no less than 150 words for Original Articles and no less than 120 words for Brief Articles; You should present *P* values where appropriate and must provide relevant data to illustrate how they were obtained, e.g.,  $6.92 \pm 3.86$  vs  $3.61 \pm 1.67$ ,  $P < 0.001$ ), and CONCLUSION (no more than 26 words).

### Key words

Please list 5-10 key words, selected mainly from *Index Medicus*, which reflect the content of the study.

### Core tip

Please write a summary of less than 100 words to outline the most innovative and important arguments and core contents in your paper to attract readers.

### Text

For articles of these sections, original articles and brief articles, the main text should be structured into the following sections: INTRODUCTION, MATERIALS AND METHODS, RESULTS and DISCUSSION, and should include appropriate Figures and Tables. Data should be presented in the main text or in Figures and Tables, but not in both.

### Illustrations

Figures should be numbered as 1, 2, 3, etc., and mentioned clearly in the main text. Provide a brief title for each figure on a separate page. Detailed legends should not be provided under the figures. This part should be added into the text where the figures are applicable. Keeping all elements compiled is necessary in line-art image. Scale bars should be used rather than magnification factors, with the length of the bar defined in the legend rather than on the bar itself. File names should identify the figure and panel. Avoid layering type directly over shaded or textured areas. Please use uniform legends for the same subjects. For example: Figure 1 Pathological changes in atrophic gastritis after treatment. A: ...; B: ...; C: ...; D: ...; E: ...; F: ...; G: ... etc. It is our principle to publish high resolution-figures for the E-versions.

### Tables

Three-line tables should be numbered 1, 2, 3, etc., and mentioned clearly in the main text. Provide a brief title for each table. Detailed legends should not be included under tables, but rather added into the text where applicable. The information should complement, but not duplicate the text. Use one horizontal line under the title, a second under column heads, and a third below the Table, above any footnotes. Vertical and italic lines should be omitted.

### Notes in tables and illustrations

Data that are not statistically significant should not be noted. \**P* <

## Instructions to authors

0.05, <sup>b</sup> $P < 0.01$  should be noted ( $P > 0.05$  should not be noted). If there are other series of  $P$  values, <sup>c</sup> $P < 0.05$  and <sup>d</sup> $P < 0.01$  are used. A third series of  $P$  values can be expressed as <sup>e</sup> $P < 0.05$  and <sup>f</sup> $P < 0.01$ . Other notes in tables or under illustrations should be expressed as <sup>1</sup>F, <sup>2</sup>F, <sup>3</sup>F; or sometimes as other symbols with a superscript (Arabic numerals) in the upper left corner. In a multi-curve illustration, each curve should be labeled with ●, ○, ■, □, ▲, △, etc., in a certain sequence.

### Acknowledgments

Brief acknowledgments of persons who have made genuine contributions to the manuscript and who endorse the data and conclusions should be included. Authors are responsible for obtaining written permission to use any copyrighted text and/or illustrations.

## REFERENCES

### Coding system

The author should number the references in Arabic numerals according to the citation order in the text. Put reference numbers in square brackets in superscript at the end of citation content or after the cited author's name. For citation content which is part of the narration, the coding number and square brackets should be typeset normally. For example, "Crohn's disease (CD) is associated with increased intestinal permeability<sup>[1,2]</sup>". If references are cited directly in the text, they should be put together within the text, for example, "From references<sup>[19,22-24]</sup>, we know that..."

When the authors write the references, please ensure that the order in text is the same as in the references section, and also ensure the spelling accuracy of the first author's name. Do not list the same citation twice.

### PMID and DOI

Please provide PubMed citation numbers to the reference list, e.g., PMID and DOI, which can be found at <http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed> and <http://www.crossref.org/SimpleTextQuery/>, respectively. The numbers will be used in E-version of this journal.

### Style for journal references

Authors: the name of the first author should be typed in bold-faced letters. The family name of all authors should be typed with the initial letter capitalized, followed by their abbreviated first and middle initials. (For example, Lian-Sheng Ma is abbreviated as Ma LS, Bo-Rong Pan as Pan BR). The title of the cited article and italicized journal title (journal title should be in its abbreviated form as shown in PubMed), publication date, volume number (in black), start page, and end page [PMID: 11819634 DOI: 10.3748/wjg.13.5396].

### Style for book references

Authors: the name of the first author should be typed in bold-faced letters. The surname of all authors should be typed with the initial letter capitalized, followed by their abbreviated middle and first initials. (For example, Lian-Sheng Ma is abbreviated as Ma LS, Bo-Rong Pan as Pan BR) Book title. Publication number. Publication place: Publication press, Year: start page and end page.

### Format

#### Journals

English journal article (list all authors and include the PMID where applicable)

- 1 **Jung EM**, Clevert DA, Schreyer AG, Schmitt S, Rennert J, Kubale R, Feuerbach S, Jung F. Evaluation of quantitative contrast harmonic imaging to assess malignancy of liver tumors: A prospective controlled two-center study. *World J Gastroenterol* 2007; **13**: 6356-6364 [PMID: 18081224 DOI: 10.3748/wjg.13.6356]

Chinese journal article (list all authors and include the PMID where applicable)

- 2 **Lin GZ**, Wang XZ, Wang P, Lin J, Yang FD. Immunologic effect of Jianpi Yishen decoction in treatment of Pixu-diarhoea. *Shijie Huaren Xiaohua Zazhi* 1999; **7**: 285-287

In press

- 3 **Tian D**, Araki H, Stahl E, Bergelson J, Kreitman M. Signature

of balancing selection in Arabidopsis. *Proc Natl Acad Sci USA* 2006; In press

Organization as author

- 4 **Diabetes Prevention Program Research Group**. Hypertension, insulin, and proinsulin in participants with impaired glucose tolerance. *Hypertension* 2002; **40**: 679-686 [PMID: 12411462 PMID:2516377 DOI:10.1161/01.HYP.0000035706.28494.09]

Both personal authors and an organization as author

- 5 **Vallancien G**, Emberton M, Harving N, van Moorselaar RJ; Alf-One Study Group. Sexual dysfunction in 1, 274 European men suffering from lower urinary tract symptoms. *J Urol* 2003; **169**: 2257-2261 [PMID: 12771764 DOI:10.1097/01.ju.0000067940.76090.73]

No author given

- 6 21st century heart solution may have a sting in the tail. *BMJ* 2002; **325**: 184 [PMID: 12142303 DOI:10.1136/bmj.325.7357.184]

Volume with supplement

- 7 **Geraud G**, Spierings EL, Keywood C. Tolerability and safety of frovatriptan with short- and long-term use for treatment of migraine and in comparison with sumatriptan. *Headache* 2002; **42** Suppl 2: S93-99 [PMID: 12028325 DOI:10.1046/j.1526-4610.42.s2.7.x]

Issue with no volume

- 8 **Banitt DM**, Kaufer H, Hartford JM. Intraoperative frozen section analysis in revision total joint arthroplasty. *Clin Orthop Relat Res* 2002; (**401**): 230-238 [PMID: 12151900 DOI:10.1097/00003086-200208000-00026]

No volume or issue

- 9 Outreach: Bringing HIV-positive individuals into care. *HRS-A Careaction* 2002; 1-6 [PMID: 12154804]

### Books

Personal author(s)

- 10 **Sherlock S**, Dooley J. Diseases of the liver and biliary system. 9th ed. Oxford: Blackwell Sci Pub, 1993: 258-296

Chapter in a book (list all authors)

- 11 **Lam SK**. Academic investigator's perspectives of medical treatment for peptic ulcer. In: Swabb EA, Azabo S. Ulcer disease: investigation and basis for therapy. New York: Marcel Dekker, 1991: 431-450

Author(s) and editor(s)

- 12 **Breedlove GK**, Schorfheide AM. Adolescent pregnancy. 2nd ed. Wiczorek RR, editor. White Plains (NY): March of Dimes Education Services, 2001: 20-34

Conference proceedings

- 13 **Harnden P**, Joffe JK, Jones WG, editors. Germ cell tumours V. Proceedings of the 5th Germ cell tumours Conference; 2001 Sep 13-15; Leeds, UK. New York: Springer, 2002: 30-56

Conference paper

- 14 **Christensen S**, Oppacher F. An analysis of Koza's computational effort statistic for genetic programming. In: Foster JA, Lutton E, Miller J, Ryan C, Tettamanzi AG, editors. Genetic programming. EuroGP 2002: Proceedings of the 5th European Conference on Genetic Programming; 2002 Apr 3-5; Kinsdale, Ireland. Berlin: Springer, 2002: 182-191

Electronic journal (list all authors)

- 15 Morse SS. Factors in the emergence of infectious diseases. *Emerg Infect Dis* serial online, 1995-01-03, cited 1996-06-05; 1(1): 24 screens. Available from: URL: <http://www.cdc.gov/ncidod/eid/index.htm>

Patent (list all authors)

- 16 **Pagedas AC**, inventor; Ancel Surgical R&D Inc., assignee. Flexible endoscopic grasping and cutting device and positioning tool assembly. United States patent US 20020103498. 2002 Aug 1

### Statistical data

Write as mean  $\pm$  SD or mean  $\pm$  SE.

**Statistical expression**

Express *t* test as *t* (in italics), *F* test as *F* (in italics), chi square test as  $\chi^2$  (in Greek), related coefficient as *r* (in italics), degree of freedom as  $\nu$  (in Greek), sample number as *n* (in italics), and probability as *P* (in italics).

**Units**

Use SI units. For example: body mass, *m* (B) = 78 kg; blood pressure, *p* (B) = 16.2/12.3 kPa; incubation time, *t* (incubation) = 96 h; blood glucose concentration, *c* (glucose)  $6.4 \pm 2.1$  mmol/L; blood CEA mass concentration, *p* (CEA) = 8.6 24.5  $\mu\text{g/L}$ ; CO<sub>2</sub> volume fraction, 50 mL/L CO<sub>2</sub>, not 5% CO<sub>2</sub>; likewise for 40 g/L formaldehyde, not 10% formalin; and mass fraction, 8 ng/g, *etc.* Arabic numerals such as 23, 243, 641 should be read 23 243 641.

The format for how to accurately write common units and quantum numbers can be found at: [http://www.wjgnet.com/2220-3192/g\\_info\\_20100725073806.htm](http://www.wjgnet.com/2220-3192/g_info_20100725073806.htm).

**Abbreviations**

Standard abbreviations should be defined in the abstract and on first mention in the text. In general, terms should not be abbreviated unless they are used repeatedly and the abbreviation is helpful to the reader. Permissible abbreviations are listed in Units, Symbols and Abbreviations: A Guide for Biological and Medical Editors and Authors (Ed. Baron DN, 1988) published by The Royal Society of Medicine, London. Certain commonly used abbreviations, such as DNA, RNA, HIV, LD50, PCR, HBV, ECG, WBC, RBC, CT, ESR, CSF, IgG, ELISA, PBS, ATP, EDTA, mAb, can be used directly without further explanation.

**Italics**

Quantities: *t* time or temperature, *c* concentration, *A* area, *l* length, *m* mass, *V* volume.

Genotypes: *gyrA*, *arg 1*, *c myc*, *c fos*, *etc.*

Restriction enzymes: *EcoRI*, *HindI*, *BamHI*, *Kho I*, *Kpn I*, *etc.*

Biology: *H. pylori*, *E. coli*, *etc.*

**Examples for paper writing**

All types of articles' writing style and requirement will be found in the link: <http://www.wjgnet.com/esps/NavigationInfo.aspx?id=15>

**RESUBMISSION OF THE REVISED MANUSCRIPTS**

Authors must revise their manuscript carefully according to the revision policies of Baishideng Publishing Group Co., Limited. The revised version, along with the signed copyright transfer agreement, responses to the reviewers, and English language Grade A certifi-

cate (for non-native speakers of English), should be submitted to the online system *via* the link contained in the e-mail sent by the editor. If you have any questions about the revision, please send e-mail to [esps@wjgnet.com](mailto:esps@wjgnet.com).

**Language evaluation**

The language of a manuscript will be graded before it is sent for revision. (1) Grade A: priority publishing; (2) Grade B: minor language polishing; (3) Grade C: a great deal of language polishing needed; and (4) Grade D: rejected. Revised articles should reach Grade A.

**Copyright assignment form**

Please download a Copyright assignment form from [http://www.wjgnet.com/2220-3192/g\\_info\\_20100725073726.htm](http://www.wjgnet.com/2220-3192/g_info_20100725073726.htm).

**Responses to reviewers**

Please revise your article according to the comments/suggestions provided by the reviewers. The format for responses to the reviewers' comments can be found at: [http://www.wjgnet.com/2220-3192/g\\_info\\_20100725073445.htm](http://www.wjgnet.com/2220-3192/g_info_20100725073445.htm).

**Proof of financial support**

For papers supported by a foundation, authors should provide a copy of the approval document and serial number of the foundation.

**Links to documents related to the manuscript**

WJJP will be initiating a platform to promote dynamic interactions between the editors, peer reviewers, readers and authors. After a manuscript is published online, links to the PDF version of the submitted manuscript, the peer-reviewers' report and the revised manuscript will be put on-line. Readers can make comments on the peer reviewer's report, authors' responses to peer reviewers, and the revised manuscript. We hope that authors will benefit from this feedback and be able to revise the manuscript accordingly in a timely manner.

**Publication fee**

WJJP is an international, peer-reviewed, OA online journal. Articles published by this journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium and format, provided the original work is properly cited. The use is non-commercial and is otherwise in compliance with the license. Authors of accepted articles must pay a publication fee. Publication fee: 600 USD per article. All invited articles are published free of charge.



百世登

**Baishideng**®

Published by **Baishideng Publishing Group Co., Limited**

Flat C, 23/F., Lucky Plaza, 315-321 Lockhart Road,

Wan Chai, Hong Kong, China

Fax: +852-31158812

Telephone: +852-58042046

E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)

<http://www.wjgnet.com>

